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ABSTRACT
The design and development of pH-sensitive peptides for cancer diagnostics provides
an opportunity to study and address fundamental questions of in vivo bio-distribution
of pH-sensitive peptides, as well as developing new targeting imaging and therapeutic
agents for acidic diseased tissue such as cancer, infections, ischemia, stroke and
others.

The main goal of the work presented here is to investigate the following problems:
-

Targeting of highly metastatic mammary tumors and spontaneous breast
tumors in transgenic mice with fluorescently labeled pHLIPs (pH (Low)
Insertion Peptides) pHLIP variants;

-

Direct imaging of pHLIP insertion and cargo translocation in vivo;

-

Targeting of mammary tumors using cyclic pH-sensitive peptides;

-

Biodistribution of different pHLIP variants conjugated with various fluorescent
dyes with the main purpose to identify the best pHLIP-based constructs for
clinical applications.

It has been shown that extracellular acidity is associated with tumor progression.
Elevated glycolysis and acidosis promote the appearance of aggressive malignant cells
with enhanced multidrug resistance. The most effective pH-sensitive tumor targeting
agents should sense pH at the surface of cancer cells, where it is expected to be the
lowest. Thus, targeting tumor acidity might represent a novel approach for the
prediction of tumor aggressiveness and delivery of therapeutic agents to tumor cells
with the greatest metastatic potential. pHLIP belongs to the class of pH-sensitive

agents capable of delivering imaging and/or therapeutic agents to cancer cells within
tumors. Also, cyclic pH-sensitive peptides containing a number of Trp and Glu
residues can be developed for imaging of acidity in tumors.
pHLIP insertion is associated with the protonation of Asp/Glu residues in the
transmembrane sequence and its inserting end. Carboxyl group protonation leads to an
increase in the hydrophobicity that further triggers transmembrane formation and
insertion of the peptide across a lipid bilayer. pHLIP insertion is predominantly unidirectional. In contrast to cell-penetrating peptides, pHLIP remains in the cellular
membrane after insertion, translocating one end across the bilayer and comes out in
the cytoplasm, while leaving the other end in the extracellular space. Therefore,
pHLIP possesses dual delivery capabilities: it can translocate cell-impermeable cargo
molecules into the cell cytoplasm or it can tether cargo molecules to the cell surface.
Also, the process of peptide folding into a membrane ensures a much higher cooperativity of the transition compared to the pH-diffusion across a membrane. A
family of novel pHLIP variants were introduced and demonstrated that tumor
targeting, blood clearance and biodistribution of this peptides can be modulated by
tuning their sequence and, as a result, their physical and chemical properties and their
interaction with the cell membrane.
For demonstrating direct imaging of pHLIP insertion and cargo translocation in vivo,
the cell-inserting end of the pHLIP-FIRE peptide has a fluorophore-fluorophore or
fluorophore-quencher pair. A pair member is released by disulfide cleavage after
insertion into the reducing environment inside a cell, resulting in de-quenching of the

probe. Thus, the fluorescence of the pHLIP-FIRE probe is enhanced upon cellinsertion in the targeted tissues, but is suppressed elsewhere due to quenching.
The cyclic pH-sensitive peptides used in this work, contain: i) single cysteine (Cys, C)
residue for conjugation purposes, ii) at least one tryptophan (Trp, W) for ability to
record fluorescence signal, iii) 3-5 protonatable glutamic acid (Glu) residues to trigger
pH-dependent interaction with membrane. As in the case of pHLIP peptides, the
presence of low pH leads to the protonation of carboxyl groups of Glu residues, which
increases peptides hydrophobicity and promotes partition of peptides in bilayer.

Thus, there is an opportunity to develop new imaging and/or therapeutic agents, which
are based on the use of pH-sensitive peptides. We have successfully established the
bio-distribution of both pHLIP and cyclic pH-sensitive peptides attached to different
fluorescent dyes and identified the best candidate for imaging and therapeutic
applications.

ACKNOWLEDGMENTS
To think that the production of this dissertation was an individual effort would be
a grave mistake. Countless people have contributed to this work in a variety of
different ways and I am forever grateful to those folks for helping me through this
great endeavor.
Several faculty members have served as mentors, helping me along the way. To
them I am thankful. Particularly, I would like to thank my advisors, Dr Yana
Reshetnyak and Dr Oleg Andreev, for their patience and guidance. I will always be
grateful for their trust and loyal support during both happy times as well as the tough
moments at URI. Their generosity has provided me with endless opportunities to grow
as a scientist. I really treasure their contagious enthusiasm for science and their
friendly advice at all times. Dr Anna Moshnikova for her scientific guidance and life
advice. Her knowledge and unlimited zeal have been major driving forces through my
graduate studies. Dr Ying Sun, for taking me on board and for helping me organize
both the comprehensive exam and the defense. I am grateful to my graduate program
committee members Dr Walter Besio, Dr Clinton Chichester and Dr John DiCecco for
their time and effort.
This dissertation has been the result of a truly collaborative effort. I am thankful
to Dr Sean Carlins from Memorial Sloan Kettering Cancer Center, as well to Dr
Dragan Golijanin and Dr Ali Amin, both from Rhode Island Hospital, for their help
and guidance on several projects.
I am endlessly thankful to Dr Felipe Vaz and Dr Luis Cunha from Minho
University, Portugal for believing in me and being supportive when all I had was an

v

idea for a project and very little lab experience. Amazing people that inspired me to
push and believe in myself.
I also want to acknowledge my friends spread across the globe, whose support
kept me sane through this long journey. They made my life outside the lab colorful.
In the end, I would like to express my eternal gratitude towards my family. I
dedicate this work to them. Each one of them had a hand in helping me achieve my
goals. I owe everything to my parents because I would not be where I am today
without the foundation they provided me with. I am thankful for their continuous love,
support and encouragement. My siblings, for listening to me when the stresses of life
became overwhelming, for their undying love and care. My beautiful nieces and
nephews, Bianca, Silviu, Otilia, Luca, and Cami for being so pure and for brightening
up my day when everything seemed too difficult. My parents and sisters in law for
welcoming me in their family. My husband John, for his love, for never trying to hold
me back, no matter how many things I attempt to drown myself with, being a strong
endowment for me, and helping me remember what really matters.
You are all a large part of who I am.

vi

PREFACE
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2. A.G. Karabadzhak, M. An, L. Yao, R. Langenbacher, A. Moshnikova, R. C.
Adochite, O. A. Andreev, Y. K. Reshetnyak, D. Engelman, pHLIP-FIRE, a Cell
Insertion-Triggered Fluorescent Probe for Imaging Tumors Demonstrates Targeted
Cargo Delivery In Vivo, ACS Chemical Biology, 9(11):2545-53 (2014).
3. D. Weerakkody, A. Moshnikova, N. S. El-Sayed, R. C. Adochite, J. Golijanin, R.
K. Tiwari, O. A. Andreev, K. Parang, Y. K. Reshetnyak, pH-Sensitive Cyclic
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Peptides conjugated with various fluorescent dyes, submitted in Journal of
Molecular Biology.
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Abstract
Extracellular acidity is associated with tumor progression. Elevated glycolysis and
acidosis promote appearance of aggressive malignant cells with enhanced multidrug
resistance. Thus, targeting of tumor acidity can open new avenue in diagnostic and
treatment of aggressive tumors and targeting metastatic cancers cells within a tumor.
pH (Low) Insertion Peptides (pHLIPs) belong to the class of pH-sensitive agents
capable of delivery of imaging and/or therapeutic agents to the cancer cells in tumors.
Here, we investigated targeting of highly metastatic 4T1 mammary carcinoma and
breast tumors in FVB/N-Tg (MMTV-PyMT)634Mul

transgenic mice with three

fluorescently-labeled pHLIP variants including well-characterized WT-pHLIP, and
recently introduced, Var3- and Var7-pHLIPs. All pHLIPs demonstrated excellent
targeting of breast tumors with signals increasing in tumors within 4 hours postinjection. Staining of non-cancerous tissue (breast muscle and fat) in transgenic mice
was minimal. pHLIPs distribution in tumors showed co-localization with 2-deoxyglucose and hypoxia marker, pimonidazole. The highest degree of co-localization of
fluorescent pHLIPs was established with lactate dehydrogenase A, which is related to
lactate production and acidification of tumors. pHLIP-based targeting imaging and
therapeutic agents present an opportunity for the monitoring of metabolic changes, and
as a means of tumor-selective delivery of therapeutic agents

2

Introduction
For a wide variety of cancers, extracellular pH is significantly more acidic than in
normal tissues. An acidic pH shift within solid tumors can regulate multiple biological
processes such as proliferation, angiogenesis, immunosuppression, invasion and
chemoresistance 1-6. Being a unique property of the majority of tumors, acidity may be
heterogeneous within a single tumor 7, 8. This heterogeneity does not correlate spatially
with tumor oxygenation; both well- and poorly-oxygenated parts of tumors can be
acidic. Exposure of cancer cells to low pH has previously been shown to promote
selection of stable, more invasive phenotypes6,

9, 10

. Therefore targeting of tumor

acidity might represent novel approach in prediction of tumor aggressiveness and
delivery of therapeutic agents to those tumor cells with the greatest metastatic
potential.
Several pH-sensitive imaging and drug delivery systems have been introduced in
which diagnostic or therapeutic agent release is specifically triggered by the acidic
tumor microenvironment 11-15. Among them are peptides of pHLIP (pH Low Insertion
Peptides) family, which represent a unique class of water-soluble membrane
polypeptides capable to undergo a pH-dependent membrane-associated folding

16, 17

.

The energy of folding is used for targeting of imaging agents to acidic tumors, as well
as translocation of polar cargo molecules across phospholipid bilayer of membrane.
Transition of pHLIPs from the membrane-surface state at neutral pH to the membraneinserted state at low pH is highly cooperative due to the accompanied coil-helix
transformation within a lipid bilayer

18-20

. The well-characterized WT-pHLIP was

employed for translocation of toxins and peptide nucleic acids into the cytoplasm of
3

cancer cells, delivery of various imaging agents and targeting of both liposomes and
gold nanoparticles to tumors and other acidic diseased tissue

21-28

. Biophysical

investigations allowed us to broaden the chemical space of pHLIP peptides and
formulate design principles to set directions for different clinical uses. We introduced
a family of rationally designed pHLIP variants and demonstrated that tuning of
sequence and, as a result, physical and chemical properties of peptides interaction with
membrane, can modulate tumor targeting, blood clearance and biodistribution

18

.

Focus of our current research is in a comparative study of WT-, Var3- and Var7pHLIPs targeting of breast tumors. The data presented here provides important
information about pHLIPs distribution in tumors and co-localization with glucose,
lactate dehydrogenase A (an enzyme involved in lactate production) and the hypoxia
marker, pimonidazole.
Materials and Methods
Synthesis and Labeling of Peptides
pHLIP variants were prepared by solid-phase peptide synthesis using Fmoc (9fluorenylmethyloxycarbonyl) chemistry and purified by reverse phase chromatography
by Dr. James I. Elliott at the W.M. Keck Foundation Biotechnology Resources
Laboratory at Yale University (New Haven, CT).
pHLIP variants were conjugated with Alexa488-, Alexa546-, Alexa647-maleimide
(Life

Technologies)

and

IR680-maleimide

(LiCor

Biosciences)

in

DMF

(dimethylformamide) at a ratio of 1:1 and incubated at room temperature for about 8
hours and then at 4ºC until the conjugation was completed. The reaction progress was

4

monitored by reverse phase HPLC. The products were lyophilized and characterized
by SELDI-TOF mass spectrometry.
The concentration of constructs was determined by absorbance using the following
molar extinction coefficients: 495=71,000 M−1·cm−1 (for Alexa488-pHLIPs),

556=104,000 M−1·cm−1 (for Alexa546-pHLIPs), 650=239,000 M−1·cm−1 (for
Alexa647-pHLIPs) and 672=165,000 M−1·cm−1 (for IR680-pHLIPs).
Cell line
The 4T1 mouse mammary tumor cell line was obtained from the American Type
Culture Collection and cultured in RPMI medium supplemented with 10% fetal bovine
serum, 10 μg/mL of ciprofloxacin in a humidified atmosphere of 5% CO2 and 95% air
at 37°C.
Tumor mouse models
Breast tumors were established by subcutaneous injection of 4T1 cells (8x105 cells/0.1
ml/flank) in the right flank of adult female BALB/c mice (about 19-22 g weight)
obtained from Harlan Laboratories. FVB/N-Tg(MMTV-PyVT)634Mul/J transgenic
female mice from Jackson Laboratory developed palpable mammary tumors at 12-15
weeks of age. All animal studies were conducted according to the animal protocol
AN04-12-011 approved by the Institutional Animal Care and Use Committee at the
University of Rhode Island, in compliance with the principles and procedures outlined
by NIH for the Care and Use of Animals.
Fluorescence whole-body and organs imaging

5

When tumors were palpable in the MMTV-Py MT mice, single tail vein injections of a
cocktail of 1 nmol of IR680-labeled pHLIPs and 10 nmoles of IR800-2DG per mouse
were performed. Control mice received the same dose of fluorescent pHLIPs and
glucose. In xenografted BALB/c mice, tumors were used when they reached
approximately 6 mm in diameter. Single tail vein injections of 5 nmol of Alexa488-,
Alexa546- and Alexa647-labeled pHLIPs (one pHLIP at the time or a cocktail of
differently-labeled pHLIPs) were performed. Pimonidazole, a marker of hypoxia, (1.5
mg) and Hoechst 33342, a blood perfusion marker (1 mg) were administered 1 hour
and 1.5 min before animal euthanization, respectively. Whole-body imaging followed
by euthanization and necropsy was performed at 24 hours post-injection. The wholebody imaging of transgenic was performed while the animals were under
ketamine/xylazine anesthesia and skin was removed from the breast area. Animals
were euthanized at 2, 4, 24 and 48 hours post-injections followed by necropsy.
Tumors and major organs of transgenic and BALB/c mice were imaged immediately
after collection. The excised tumors were embedded in Tissue-Tek optimal cutting
temperature

(OCT)

compound

and

stored

at

-80oC

until

used

for

immunohistochemical analysis.
Imaging of Alexa-pHLIPs and IR-pHLIPs/IR-glucose were carried out using a FX
Kodak in-vivo image station and an Odyssey IR scanner (Li-Cor Biosciences),
respectively, using various magnifications and depth distances. Mean fluorescence
intensity of tumor and organs was calculated using Kodak and Image J software. The
contrast index (CI) was calculated according to the equation:

6

where Ftumor , Fmuscle and Fbackg are the mean fluorescence intensities of tumor, muscle
and background signal measured for control mice non-injected with fluorescent
constructs.
Immunofluorescence staining and imaging of tumor sections
Frozen breast tumor tissues were sectioned at a thickness of 10 μm using a Vibratome
UltraPro 5000 Cryostat. Sections were mounted on microscope slides, dried in air, and
washed with deionized water. Tumor sections with pHLIPs-cocktail were analyzed
without further processing, whist the remaining sections were fixed and stained. Slides
were fixed in 4% paraformaldehyde (Sigma-Aldrich) for 12 minutes and washed with
Dulbecco’s Phosphate Buffered Saline (Life Technologies). The slides were dried in
air and blocked using a mixture of 10% Goat serum (GeneTex), 1% bovine serum
albumin (Life Technologies) and 0.3% Triton X-100 (Sigma-Aldrich) in phosphate
buffered saline (Life Technologies) for 30 minutes. Then, immunofluorescence
staining for lactate dehydrogenase A (LDHA) and pimonidazole was performed. For
LDHA staining, rabbit polyclonal (NBP1-48336, Novus Biologicals) was used at
1:100 dilution, with goat anti-rabbit Alexa-568 (Life Technologies) at 1:100 for
secondary detection. For pimonidazole staining, FITC-conjugated mouse monoclonal
anti-pimonidazole antibody (Natural Pharmacia International Inc.) was used at 1:20
dilution. Following fluorescence imaging, the same sections were then stained with
H&E.
Fluorescence and brightfield images were acquired at 4x magnification using an
Olympus BX60 fluorescence microscope equipped with a motorized stage (Prior
7

Scientific Instruments Ltd.) and coolsnap EZ CCD (Photometrics) and CC12 RGB
camera (Olympus Scientific). Whole-tumor montage images were obtained by
acquiring multiple fields, followed by alignment using MicroSuite Biologic Suite
(version 2.7; Olympus).
Results
The focus of our work was targeting of breast tumors by three pHLIP variants recently
selected for pre-clinical development:
WT: ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT
Var3: ACDDQNPWRAYLDLLFPTDTLLLDLLW
Var7: ACEEQNPWARYLEWLFPTETLLLEL
Each peptide has a single Cys residue at the N-terminus for conjugation with
fluorescent Alexa or IR dyes. Labeled peptides were purified prior in vivo use. We
selected two different breast tumor models for testing of pHLIPs tumor targeting: i)
the highly tumorigenic and invasive 4T1 mammary carcinoma and ii) FVB/N-Tg
(MMTV-PyMT)634Mul transgenic mouse model.
Targeting 4T1 mammary carcinoma
Small 4T1 tumors (tumor volume < 150 mm3) generate significant level of lactate and
serve as a good model of an aggressive, acidic tumor 29. pHLIP variants labeled with
Alexa546 showed significant targeting of tumors with minimal signal accumulation in
liver, kidney and muscle (Figure 1a-d). The signal in tumors was increasing up to 4 hrs
post-injection, and then declined within 48 hrs. The highest uptake in tumor was
observed for Var3. At 48 hrs post-injection the signal in tumor was still higher than
the background fluorescence, while fluorescence in muscle and liver was at the level
8

of autofluorescence. Var7 demonstrates fast clearance and steady decay of fluorescent
signal from 2 to 24 hrs in all organs except tumor, where the maximum signal was
reached at 4 hrs post-injection. For Var3, the renal fluorescence signal was maximal
at 24 hrs, indicating a slower clearance profile of this pHLIP variant. The optimal
tumor targeting was achieved with Var3, which showed a contrast index of 5 at 2-4 hrs
and 19 at 24 hrs post-injection (Figure 2b). The contrast index for Var7 was increasing
from 3, 5 and up to 19 for 2, 4 and 24 hrs post-injection, respectively. We did not
calculate values of contrast index for time point of 48 hrs, since signal in muscle was
at the level of background.
We compared the distribution of fluorescent-pHLIPs in both small and necrotic large,
4T1 tumors. The representative images of tumors cut into halves are shown on Figure
1e and f. In contrast to the smaller tumors, where the signal was homogeneously
distributed within the entire tumor mass with maximal accumulation in the center of
the tumor, the fluorescent signal in the necrotic core of the larger tumors was minimal.
Previously, we proved pH-dependent tumor targeting by WT-pHLIP27,
pHLIP

variants

also

show

pH-dependent

tumor

staining,

28, 30

but

. Novel

different

pharmacokinetics18. In this study, we compared cellular localization and distributions
of different pHLIPs in tumors. Frozen sections were prepared from tumors collected at
4, 24 and 48 hrs after administration of a cocktail of pHLIPs labeled with different
fluorescent dyes: Alexa488-Var7, Alexa546-Var3 and Alexa647-WT given as a single
tail vein injection (Figure 3).

We selected later time points to minimize the

concentration of the peptides in blood. The distribution of all pHLIPs in tumors was
identical. The intensity profiles for all pHLIPs obtained from the different areas of
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tumor sections were very similar, with minor differences in general background. Thus,
despite on the fact that pHLIP variants show different blood clearance profile, the
cellular distributions were identical and all variants could be used as markers of tumor
acidity.
Immunohistochemical analysis of breast tumor sections (small 4T1 tumors) revealed
co-localization of fluorescent pHLIPs with hypoxia marker, pimonidazole, and
excellent co-localization with lactate dehydrogenase A (LDHA) (Figure 4).
Targeting breast tumors in transgenic mice
It has been previously established that breast tumor progression from benign to
metastatic correlates with age in FVB/N-Tg (MMTV-PyMT)634Mul transgenic
mouse model

31-33

, with invasive tumors developing in mice of age 12 weeks and

older. We used mice with an age range from 12 to 15 weeks to investigate distribution
of pHLIPs in spontaneous invasive breast tumors. Tumor and organs were analyzed at
24 hrs after iv administration of Alexa546- or IR680-pHLIPs given as a single
injection, or in a mixture with the fluorescent non-metabolizible 2-deoxyglucose
IR800-2DG. We observed pHLIP- targeting of breast tumors in transgenic mice with a
minimal level of fluorescence from control mice, or detectable signal in muscle at 24
hrs post-injection (Figure 5a, b). Higher tumor uptake of Var3 was observed, along
with higher signal in muscle at 24 hrs compared to the other pHLIPs. Fluorescent
signal for WT and Var7 was comparable to the signal from fluorescent 2deoxyglucose, which was given at concentrations 10 times higher than pHLIPs.
Multiple tumors collected from the same mouse targeted by both IR680-Var3 and
IR800-2DG are shown on Figure 5c. We observed heterogeneity in distribution of
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IR800-2DG. Detailed analysis of 2-deoxygluoce and pHLIPs distribution in tumors
indicates that accumulation of 2-deoxyglucose correlates with the accumulation of
pHLIPs (Figure 5d and e). However pHLIPs also demonstrate targeting of adjacent
spots.
Analysis of histological sections of breast tumors indicates that pHLIPs can clearly
differentiate between regions of primarily tumor cells and non-malignant stromal
tissues (Figure 6a, b, c). Regions consisting mainly of tumor cells stained strongly
with all pHLIP variants. Uptake of pHLIPs was observed in poorly-perfused tumor
regions (indicated by low Hoechst 33342 staining), which also accumulated the
hypoxia marker pimidazole (Figures 6 and 7). However, we observed the highest
degree of pHLIP co-localization with the lactate dehydrogenase A (LDHA) enzyme,
confirming that uptake of pHLIP is closely related to the production of acidic glucose
metabolites in this model system.
Discussion
Tumors of the same organ and cell type can have remarkably diverse appearances in
different patients, which apply significant restriction for the use of targeting
approaches based on over expression of particular protein biomarkers. Heterogeneity
of the cancer cell population within a single tumor is assumed to lead to diminished
treatment response. Cytotoxic therapies, whilst treating the majority of cancer cells,
may spare multidrug resistant clones leading to tumor relapse and treatment failure
35

34,

. Moreover, this transient depopulation of sensitive tumor cells by chemotherapeutic

agents may provide a growth advantages to the surviving cells, leading to outgrowth
of resistant clones35. It is therefore important to develop targeted imaging agents,
11

which can reflect the underlying tumor microenvironment, and allow for the targeted
therapy of otherwise resistant cell clones. pH-responsive imaging and therapeutic
probes could be particularly well-suited to this role, as, decreased extracellular pH is a
general property of tumor microenvironment reflective of tumor aggressiveness, and
the most malignant cells within a tumor mass are glycolytic and acidic.
Previously we demonstrated that water soluble membrane peptide, WT-pHLIP, can
deliver optical, PET and SPECT imaging agents to the primary tumors and metastatic
lesions in a pH-dependent manner, and distinguish between aggressive and nonmetastatic tumors26-28,

30

. The main goal of this study was to establish pHLIP

distribution in breast tumors and evaluate co-localization with other markers of
stressed tumor microenvironment. In this case, we compared distribution of pHLIPs
with a fluorescent glucose analog, 2-deoxyglucose, (indicating elevated glucose
uptake), lactate dehydrogenase A (indicating glycolytic metabolism) and pimonidazole
(a marker of tumor hypoxia). We selected two well-characterized breast cancer
models: i) the murine 4T1 xenograft model, which closely mimic stage IV of human
breast cancer

36-38

, and ii) FVB/N-Tg (MMTV-PyMT)634Mul transgenic mouse

model, which show different degree of disease progression, such as mammary
hyperplasia, DCIS and invasive cancer at different ages of animals ranging from week
4 to 12, respectively 31-33.
Both 4T1 tumors and breast tumors in transgenic mice were targeted very well by
fluorescently-labeled pHLIP variants, with minimal signal observed in other organs.
We carried out our imaging studies on small, well-perfused 4T1 tumors (about 0.2 g in
mass). Further growth of 4T1 tumors (up to mass of 0.5-0.6 g) leads to the appearance
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of a necrotic core, which did not accumulate pHLIPs. This observation is consistent
with previous studies showing that significant necrosis observed in enlarging 4T1
tumors is associated with lower levels of lactate production29. The fluorescent signal
from pHLIPs in small 4T1 tumors reached maximum level at 4 hours post-injection.
The highest signal was observed for Var3, which was over 2-fold greater than that
observed with IR800-2DG (a fluorescent glucose analog).
The detailed analysis of the distribution in tumors of three pHLIP variants (WT, Var3
and Var7) labeled with different fluorescent dyes and given as a cocktail in a single iv
injection showed a high degree of co-localization. Histological analysis of tumor
sections from the transgenic mice clearly indicates a minimal level of non-tumor
(stromal) staining and elevated staining of tumor-containing regions by the three
pHLIPs. Var3 and Var7 were recently introduced as novel pHLIP variants, which
show higher tumor targeting and fast blood clearance, respectively18, and are able to
target pancreatic tumors in various mouse models39. Despite on the difference in
pharmacokinetics of pHLIP variants, Var3 and Var7 demonstrate distribution in
tumors identical to the well-characterized WT-pHLIP. The pharmacokinetic properties
of Var3 and Var7 could be suited well for imaging of tumor acidity by MRI/optical
and PET/SPECT, respectively.
Using IR800-2DG we observed that the distribution of the glucose analog in tumors is
heterogeneous, and correlates well with pHLIPs distribution. Regions of elevated
pHLIPs uptake correlate with the hypoxia marker pimonidazole as well. At the same
time, pHLIPs also target adjacent spots to 2-doxyglucose uptake and show
accumulation in non-hypoxic tumor regions. The highest co-localization of pHLIPs
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was seen with lactate dehydrogenase A in both transgenic and 4T1 small tumors.
LDHA expression is partially regulated by the hypoxia-inducible HIF1 transcription
factor, as is the glucose transporter GLUT-1. Our observation of a positive correlation
between pHLIP uptake and markers of glucose transport and metabolism strongly
implies that pHLIP is specifically accumulated in tumor regions displaying typical
characteristics of a stressed microenvironment, such as hypoxia, elevated glucose
uptake and glycolytic metabolism. Increased LDHA expression, with consequent
increases higher lactate production and generation of hydrogen ions, would be
expected to correlate most closely with pH-dependent uptake of pHLIP, as was
observed in this study.
Despite an evident correlation between glucose uptake, lactate production and tumor
acidification, it was shown that [18F]2-deoxy-2-fluoro-D-glucose positron emission
tomography ([18F]FDG-PET) imaging was significantly less sensitive to differences in
the metabolic phenotypes of tumors compare to the lactate-MRSI (magnetic resonance
spectroscopic imaging)29. Although MRSI can provide additional information about
metabolic activities in tumors, it is not yet widely implemented in a clinical setting.
The potential exists for pHLIP to provide imaging data of a similar nature to lactateMRSI, but with a clear path to rapid clinical translation . Use of any of three of pHLIP
variants labeled with PET or SPECT agents (such as

18

F,

64

Cu,

99

Tc) could allow

monitoring of metabolic changes in human tumors over time, or in response to
therapeutic intervention. In addition, pHLIP peptides could be used for delivery of
therapeutic cargoes to tumors, which might target the most aggressive cancer cell
clones.
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Figures

Figure 1. Distribution of pHLIPs in small breast 4T1 tumors, muscle, kidney and
liver. Fluorescent images of organs obtained at 2 hrs (a), 4 hrs (b), 24 hrs (c) and 48
hrs (d) after i.v. administration of WT, Var3 and Var7 peptides conjugated with
Alexa546 are shown. Distribution of pHLIPs is different in small (e) and big (f) 4T1
21

tumors (tumor mass is indicated in upper right corner). The necrotic region of the big
breast 4T1 tumor is indicated by arrow.

22

Figure 2. Time-dependent biodistribution of Alexa546-pHLIPs quantified by ex-vivo
mean fluorescence in breast 4T1 tumors, muscle, kidney and liver (a). Contrast index
was calculated for the breast 4T1 tumors (b). The values are given in Supplementary
Tables 1 and 2.
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Figure 3. pHLIPs distribution in breast 4T1 tumors. Fluorescence images of tumor
sections for 4 hrs (a), 24 hrs (c) and 48 hrs (e) post-injections of cocktail of Alexa647-

24

WT, Alexa546-Var3 and Alexa488-Var7 are shown. Intensity profiles of the
fluorescent signal of various pHLIPs in the different lines are shown in b, d, f.
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Figure 4. Immunohistochemical staining of 4T1 tumors. pHLIPs distribution
(Alexa546-pHLIPs, red), LDHA staining (yellow), hypoxia (Pimonidazole, green) and
blood flow (Hoechst, blue), are compared on tumor sections (a, c, e). Intensity profiles
of the fluorescent signals in the highlighted regions are shown on b, d, f.
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Figure 5. Tumor targeting by IR680-pHLIPs and IR800-2DG in transgenic mice.
Whole-body NIR fluorescence images of control and transgenic mice were obtained at
24 hrs after i.v. administration of IR680-pHLIP, tumor is indicated by arrow (a).
Averaged mean fluorescence of IR680-pHLIPs and IR800-2DG in tumors and muscle
is calculated (b). Distributions of IR680-pHLIPs (green) and IR800-2DG (red) in
breast tumors are compared (c, d). Intensity profiles of the fluorescent pHLIPs and
glucose in the highlighted regions are shown on e.
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Figure 6. Immunohistochemical staining of tumors from transgenic mice. Histology
(H&E), blood flow (Hoechst, blue), pHLIPs distribution (Alexa546-pHLIPs, red),
LDHA staining (yellow) and hypoxia (Pimonidazole, green) are compared on tumor
sections (a, b, c). The non-cancerous regions are indicated by arrows. Intensity
profiles of the fluorescent signals in the highlighted regions are shown on d.
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Figure 7. Magnified images of sections of breast tumors from transgenic mice. Blood
flow (Hoechst, blue), pHLIPs distribution (Alexa546-pHLIPs, red), LDHA staining
(yellow) and hypoxia (Pimonidazole, green) are compared on tumor sections (a, b, c).
Hypoxic regions indicated by stars.
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SUPPORTING INFORMATION
Targeting Breast Tumors with pH (Low) Insertion Peptides
Ramona-Cosmina Adochite, Anna Moshnikova, Sean D. Carlin, Renato A. Guerrieri,
Oleg A. Andreev, Jason S. Lewis, Yana K. Reshetnyak

Table S1. Mean fluorescence (and St. D.) of 4T1 mammary tumors, muscle, kidney and
liver. The control means mice injected with the The data are shown on Figure 2a. The plevel values (shown by asterisks) were calculated based on the two-tailed test between
mean of fluorescence in tumor vs muscle, liver and kidney at various time points for
different pHLIPs. The signal in tumor is statistically significantly higher compared to the
signal in organs, except Var7 signal in kidney at 24 and 48 hrs.

Organs

Tumor

Muscle

Liver

Kidney

Time
postinject
ion
2h

WT
n= 6

Var3
n= 6

Var7
n= 6

3856.7 ± 1058.5

4664.5 ± 720.4

3267.1 ± 689.9

4h

5716.8 ± 1284.8

5809.9 ± 880.4

3514.1 ± 622.9

163.1 ±

24 h

1287.1 ± 290.4

2773.0 ± 600.3

810.4 ± 196.2

19.4

48 h

999.5 ± 129.8

1229.6 ± 281.9

516.7 ± 128.9

2h

1057 ± 137.8 (***)

963.4 ± 120.8 (***)

1150.2 ± 126.6 (***)

4h

1212.0 ± 189.4 (***)

1117.9 ± 167.3 (***)

757.0 ± 34.9 (***)

146.7 ±

24 h

294.4 ± 23.2 (***)

297.7 ± 28.6 (***)

191.2 ± 8.3 (***)

8.4

48 h

193.6 ± 18.1 (***)

201.1 ± 13.3 (***)

179.4 ± 16.1 (***)

2h

1671.7 ± 148.7 (***)

1670.3 ± 409.5 (***)

805.8 ± 112.4 (***)

4h

1984.0 ± 27.9 (***)

1448.7 ± 317.7 (***)

623.6 ± 77.2 (***)

149.8 ±

24 h

502.5 ± 85.5 (***)

303.4 ± 64.4 (***)

217.0 ± 21.8 (***)

5.8

48 h

357.2 ± 24.5 (***)

254.9 ± 37.2 (***)

193.6 ± 20.6 (***)

2h

1235.5 ± 182.2 (***)

880.3 ± 51.2 (***)

1346.8 ± 145.8 (***)

4h

1099.2 ± 254.3 (***)

1148.4 ± 326.7 (***)

1045.2 ± 144.4 (***)

164.7 ±

24 h

544.8 ± 85.9 (***)

12887 ± 253.3 (***)

821.3 ± 122.5 (ns)

2.0

48 h

485.4 ± 126.5 (***)

918.5 ± 225.9 (*)

690.5 ± 259.6 (ns)
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Autofluoresc
ence
n=4

Table S2. Contrast index calculated based on the data presented in Table 1. The data
are shon on Figure 2b. Table contains Mean values and St.D.
Time post-

WT

Var3

Var7

injection

n= 6

n= 6

n= 6

2h

4.1 ± 0.9

5.6 ± 0.4

3.2 ± 0.9

4h

5.2 ± 0.6

5.9 ± 0.9

5.5 ± 0.8

24h

12.8 ± 5.7

18.8 ± 4.2

19.1 ± 7.2

Table S3. Mean fluorescence (and St.D.) are given. The n is the number of cases. The
data are plotted on Figure 2a

Organs
Muscle
Tumor

IR680-WT

IR680-Var3

IR680-Var7

IR800-2DG

130.8 ± 33.4

867.5 ± 276.7

40.04 ± 0.49

99.4 ± 51.8

(n = 3)

(n = 3)

(n = 3)

(n = 9)

694.6 ± 381.7

2834.2 ± 1213.1

233.3 ± 106.3

1050.1 ± 422.5

(n = 33)

(n = 29)

(n = 33)

(n = 99)
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Abstract
We have developed an improved tool for imaging acidic tumors by reporting the
insertion of a transmembrane helix: the pHLIP-Fluorescence Insertion REporter
(pHLIP-FIRE). In acidic tissues, such as tumors, peptides in the pHLIP family insert
as -helices across cell membranes. The cell-inserting end of the pHLIP-FIRE peptide
has a fluorophore-fluorophore or fluorophore-quencher pair. A pair member is
released by disulfide cleavage after insertion into the reducing environment inside a
cell, resulting in de-quenching of the probe. Thus, the fluorescence of the pHLIP-FIRE
probe is enhanced upon cell-insertion in the targeted tissues, but is suppressed
elsewhere due to quenching. Targeting studies in mice bearing breast tumors show
strong signaling by pHLIP-FIRE, with a contrast index of ~ 17, demonstrating (i)
direct imaging of pHLIP insertion and (ii) cargo translocation in vivo. Imaging and
targeted cargo delivery should each have clinical applications.
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Introduction
Imaging technologies are an important focus for improving the diagnosis of cancer,
and for guiding surgical and radiation therapies. Among the new tools, perhaps the
greatest recent growth has come in the field of fluorescence imaging, with numerous
new technologies now being adapted for clinical use1, 2. One promising approach is the
targeting of tumor biomarkers with fluorescent agents, allowing surgeons to visualize
tumors in real-time during an operation. This advance has the potential to improve the
success of surgical interventions by giving an active real-time marker of tumor
borders, which are often hard to distinguish from the surrounding healthy tissue3. The
primary goal in imaging-agent design is a high target-to-background ratio: agents
should contribute minimal background, but have high local concentrations at intended
target sites. The "self" nature of targeted markers often leads to background signals
too high for effective discrimination of tumors. A further complication lies in the
diverse nature of human cancers. Since heterogeneous marker expression is often
found within regions of a tumor, and further since no two cancers are identical, it is
unlikely that a single marker can be relied upon4.
As an alternative to biomarker targeting, we have suggested that the acidic
environment within solid tumors may be exploited for targeting by the pH (Low)
Insertion Peptide (pHLIP) family5. Malignant tumors exhibit elevated uptake and
consumption of glucose, as well as metabolite buildup and hypoxia due to inadequate
blood supply, leading to tumor acidosis from the Pasteur and Warburg effects6-8. As a
result, the extracellular environment in virtually all solid tumors is acidic (pH ~ 6.0 -
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6.5)9,

10

, and more aggressive tumors are more acidic

11

. Extracellular acidity may

therefore be a general biomarker for targeting malignant tumors.
The original pHLIP is a 36-amino-acid peptide, and a number of versions with
different properties have now been found that constitute the family of pHLIPs5. A
pHLIP exists as a soluble, unstructured monomer with an affinity for cell membranes
at physiological pH. The adsorption to a model POPC membrane at high pH is
accompanied by the release of about 5-7 kcal mol-1 of energy5, 12. At low pH (pH ≤
~6), pHLIP folds to form a transmembrane -helix, inserting its C-terminus across the
cell membrane. The transition proceeds with an additional release of 1.5-2 kcal mol-1
of energy. This pH-dependent insertion is triggered by protonation of carboxyl groups
on residues in the peptide transmembrane region and peptide inserting end. The
protonation effectively increases the overall hydrophobicity of pHLIP, permitting the
insertion13.

Serendipitously, the extracellular pH at which pHLIP undergoes its

insertion transition corresponds closely to the extracellular pH produced in acidic solid
tumors. Using peptides covalently modified with fluorescent dyes at the non-inserting
N-terminus, pHLIP has been shown to target both spontaneous and implanted tumors
in small animal models, although slow background clearance has limited the contrast
ratios that can be attained14-18. The insertion energy can be used to deliver cargo
molecules into cells, by biasing the equilibrium between surface and inserted forms in
favor of the transport of cell-impermeable polar molecules attached to the Cterminus19-21.

While such delivery has been explored in cells, the step of

demonstrating cytoplasmic delivery in tumors in an animal had not been taken before
the work we report here.
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To improve contrast and to document transmembrane insertion delivery in vivo, we
have developed the pHLIP Fluorescence Insertion REporter system (pHLIP-FIRE),
with the main goal as enhancing fluorescent signal upon insertion into cells in diseased
tissue. pHLIP-FIRE peptides possess neighboring lysine and cysteine residues in the
cell-inserting, C-terminal end. The lysine side-chain is irreversibly covalently linked
to a fluorophore via an amide bond. The neighboring cysteine side-chain is covalently
linked by a disulfide bond to a fluorescence quencher or another fluorophore (for selfquenching). When these moieties are both present on the peptide, the fluorescence is
quenched, but upon insertion of the C-terminus into the reducing environment of a
living cell, the quenching moiety is released by disulfide reduction, leading to the
dequenching of the fluorophore emission (Figure 1). The pHLIP-FIRE strategy aims
to increase the contrast of fluorescence imaging in vivo by quenching background
signals. We report tumor imaging with improved sensitivity, as well as demonstrating
for the first time pHLIP insertion and cargo delivery in vivo.
Results and Discussion
Our strategy of pHLIP-FIRE is based on fluorescence quenching, which occurs upon
close proximity of either two fluorophores (homo-quenching and H-dimer formation)
or a fluorophore-quencher pair (hetero-quenching). When one of the members of a
pair is released, in our case by disulfide cleavage in the cytoplasm, the result is greatly
enhanced observable fluorescence. Accordingly, we designed and synthesized two
pHLIP-FIRE constructs. The first construct, pHLIP-T-T, carries two TAMRA
fluorophores that are self-quenched by forming an H-dimer, with one attached to
pHLIP via a disulfide bond. The second construct, pHLIP-T-Q, has a TAMRA-QSY9
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pair, where the quencher (QSY9) is attached to pHLIP via a disulfide bond. To control
for quenching activity, a pHLIP with a single, unquenched TAMRA dye covalently
linked to a C-terminal cysteine via a thioether bond was also synthesized and tested.
The constructs used in this study are as follows:
pHLIP-T-T:
AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTK(TAMRA)C(TAMRA)G

pHLIP-T-Q:
AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTK(TAMRA)C(QSY9)G
pHLIP-T:
AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTC(TAMRA)
Chemical fluorescence dequenching. The spectral properties of each pHLIP-FIRE
construct were investigated in solution in the absence and presence of a reducing
agent. Glutathione (GSH) is the primary reducing agent in living cells, with an
intracellular concentration of up to 10 mM, depending upon the intracellular
compartment and the cell cycle22. We used 1, 3, or 10 mM concentrations of
glutathione to simulate reductive and physiologically reasonable intracellular
conditions. pHLIP-FIRE dequenching was observed by absorbance and fluorescence
spectroscopy. The absorbance peak of the TAMRA-TAMRA H-type dimer (in pHLIPT-T) is blue-shifted to 524 nm from the usual monomer TAMRA absorbance
maximum at 555 nm23. The blue-shifted TAMRA-TAMRA dimer absorbance peak
was replaced by an augmented 555 nm TAMRA peak following disulfide reduction in
the pHLIP-T-T peptide with 10 mM glutathione. As expected, in contrast to pHLIP-TT, the shape of the absorbance spectrum of pHLIP-T-Q does not change significantly
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after the cleavage of the S-S bond and resulting quencher separation (Figure 2a). The
activation of the pHLIP-T-Q and pHLIP-T-T probes were each monitored by changes
in the TAMRA fluorescence signal. After incubation with 10 mM glutathione, the
pHLIP-T-Q or pHLIP-T-T fluorescence was excited at 555 nm, and emission was
followed at its 580 nm maximum (Figure 2b). An increase in emission intensity was
observed over time following the addition of glutathione (1, 3, or 10 mM).
Fluorescence intensity was plotted as a function of time and fit using a single
exponential function (Figure 2d). The fluorescence of each pHLIP-FIRE construct was
significantly quenched when compared to the emission of pHLIP-T (Figure 2c). The
addition of glutathione did not alter the fluorescence intensity of pHLIP-T, whereas a
7 to 18-fold increase in fluorescence intensity was observed for the pHLIP-FIRE
constructs after 3 hours. Our data show the expected higher dequenching signal for
pHLIP-T-T compared to pHLIP-T-Q, since two moles of TAMRA are dequenced in
the T-T case. The kinetics of activation depend on the glutathione concentration: At 10
mM GSH, the rates are k = 4.7 hr-1 and 3.4 hr-1 for pHLIP-T-T and pHLIP-T-Q
respectively, whereas at 1 mM GSH, the rates are k = 1.1 hr-1 and 0.4 hr-1
(Supplementary Table 1).
The pH-dependent interactions of pHLIP-FIRE peptides with artificial membranes
were followed by Circular Dichroism (CD). Peptides were incubated with 100-nm
POPC liposomes overnight in pH 8 phosphate buffer and the pH was dropped rapidly
to pH 4 by the addition of concentrated HCl. When measured alone in solution or in
the presence of liposomes at pH 8, pHLIP-FIRE exhibited CD spectra characteristic of
an unstructured peptide, with a negative ellipticity peak around 200 nm. When the pH
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was dropped to 4, a characteristic CD α-helical signal was observed, with two negative
ellipticity peaks at 208 nm and 222 nm and a positive peak at 195 nm. The CD data
show that the pHLIP-FIRE constructs exhibit the three states of pH-dependent
membrane insertion characteristic of pHLIP peptides (Figure 3).
pHLIP-FIRE activation in cultured cells. pH-triggered activation of each pHLIPFIRE probe was tested in cultured cells grown at normal pH medium (HeLa and COS7) or adapted for low pH growth (A549). HeLa and COS-7 cells were incubated with
pHLIP-FIRE peptides (1 µM) for 20 minutes at room temperature (~ 22°C) either at
pH 7.4 or at pH 6.1 DPBS buffer in 96-well plates. Cells were then washed three times
with DPBS buffer (pH 7.4 or pH 6.1) and DMEM (pH 7.4 or pH 6.1) was added
before measurements were performed at each experimental pH. TAMRA fluorescence
was measured immediately after washing (time zero used for normalization), then at
multiple time points for up to two days following the incubation and wash steps.
TAMRA fluorescence intensity steadily increased over two days following incubation
at low pH conditions to a maximum intensity of 16-fold over the zero time point.
Higher TAMRA fluorescence signals (8-16 fold increase) were observed in cells
(HeLa and COS-7) incubated with pHLIP-FIRE peptides at pH 6.1 as compared to the
fluorescence increase following incubation and washing at pH 7.4 (2-4 fold increase)
(Figure 4). Activation of the pHLIP-FIRE at neutral pH might occur due to i)
membrane insertion of some amount of the construct at pH 7.2-7.4, since there is an
equilibrium between inserted and surface locations of the peptide, or ii) endocytotic
uptake of the peptide adsorbed at the membrane surface, especially since the time
course of the experiment is several days, or both. The fluorescence data were fitted
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with a single exponential non-linear regression. For constructs at low pH the rate
constants were found to be ~ 0.8 – 1.38 hr-1 with a positive linear slope of 0.08 – 0.23
(Figure 5), similar to rates observed in the chemical dequenching experiments with
glutathione concentrations from 1 – 3 mM (Supplementary Table 1). The linear
component of the fitting signal may arise from a second population of pHLIP-FIRE, in
which some other mechanism is involved, such as non-specific endocytotic uptake of
the constructs, producing slow kinetics. Interestingly, the linear component of nonspecific uptake is higher for HeLa cells than COS-7 cells, possibly indicating that
different cell types internalize the peptide via different pathways and at different rates.
The A549 cells adapted to low pH growth were incubated with pHLIP-FIRE peptides
(1 µM) or the unquenched control peptide, pHLIP-T (1 µM), for 20 minutes as
described above, then washed cells were kept in culture at pH 6.1. Fluorescence was
measured at intervals for four days after treatment. pHLIP-T showed no significant
change in fluorescence (2-fold background increase) over the course of these
measurements, whereas both pHLIP-T-T and pHLIP-T-Q showed an 8- to 10-fold
increase in fluorescence at 74 hours after incubation (Figure 6). pHLIP itself doesn’t
show signs of toxicity in cells or animals5, 21.
Confocal Microscopy of pHLIP-T-T Activation in Cells. We used confocal
microscopy to visualize pH-dependent TAMRA release and distribution inside
cultured cells. The cells were treated with 1 µM of pHLIP-T-T as described above. 30
minutes before imaging, the cells were treated with Hoechst to stain the nuclei. When
C-terminuis of the construct is inside the cytoplasm we expect to see TAMRA
fluorescence signal throughout the cytoplasm due to release of the disulfide linked
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TAMRA. Confocal microscopy shows that this is the case at pH 6.1 but not at pH 7.4.
Interestedly, we observed some “punctate” fluorescence at pH 7.4, which might be
attributed to endocytic uptake of the construct by HeLa (Figure 7).
Imaging in vivo. Because of their pH-dependent interaction with membranes, pHLIP
peptides have been shown to target and persistently label cells in acidic tissues, such
as cancerous tumors, in vivo 24, 25. pHLIP peptides have also been successfully used to
translocate cell-impermeable molecules across the membranes of cultured cells in a
pH-dependent manner

19, 20

. Here, we take the next step: demonstrating targeted

delivery into tumor cells in vivo.
Balb/c mice bearing implanted 4T1 murine breast tumors were used to assess the
tumor targeting and biodistribution properties of pHLIP-FIRE in comparison with
pHLIP-T. Mouse tumors were established by subcutaneous injection of 4T1 cells (8 x
105 cells) in the right flank of each mouse. When tumors reached 5 to 6 mm in
diameter, each of the pHLIP-FIRE peptides and the unquenched control pHLIP-T
were given as single injections into the tail veins of groups of mice. Peptides were
injected at ~1 mg/kg, with adjustments made to deliver equimolar dosages of the
varied peptide constructs. Animals were euthanized at 24 or 48 hours following
injection, and necropsy was performed immediately thereafter. Tumors and major
organs were excised and imaged on an FX Kodak in vivo image station. Imaging was
performed for each animal using a uniform set of illumination and exposure
parameters in order to allow accurate comparison of the resulting intensities (Figure 8
a, b). The mean TAMRA-fluorescence intensities for pHLIP-FIRE constructs and for
pHLIP-T are shown (Figure 8 c) and their numeric values are given in Supplementary
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Table 2. Strong tumor targeting was observed in each case, with very little off-target
labeling detected in muscle, heart, spleen and lungs. The fluorescence intensity was
the highest in tumors labeled with pHLIP-T-Q and was the lowest in muscle for the
pHLIP-T-T construct. Also, we observed an elevated uptake of the pHLIP-FIRE
constructs in liver and kidneys compared to pHLIP-T.
To quantify improvement in tumor discrimination using the pHLIP-FIRE constructs as
a result of the lower background we compared the fluorescence intensities of tumors
and non-targeted muscle tissues and calculated contrast index (C.I.), defined as the
corrected tumor to background ratio:

where Fltumor, Flnorm, and Flauto are the mean fluorescence intensities of tumors, skeletal
muscle, and the autofluorescence background signal from corresponding tissues in an
untreated mouse, respectively.
The contrast index was substantially greater for the pHLIP-FIRE constructs than the
unquenched pHLIP-T. After 24 hrs, the mean contrast indices were 11.7, 16.6, and 7.3
for pHLIP-T-T, pHLIP-T-Q and pHLIP-T respectively (Figure 8 d). Thus, we
achieved over 2-fold improvement in contrast using pHLIP-T-Q compared with the
unquenched fluorescent probe, pHLIP-T. Because the pHLIP-FIRE signal in the
muscle is close to zero after 48-hours, we could not use C.I. as a parameter for
quantitative measurement of the contrast. Division by a close-to-zero value results in
high deviation in the mean value, which leads to statistically weak representation.
However, we can calculate the ratio of average signals in tumor and muscle. These
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parameters show similar values at both 48 and 24 hrs time points. From this we
conclude at least the same contrast at 48 hrs as at 24 hrs.
Here, we report a new tool, pHLIP-FIRE, for improved tumor to muscle contrast, and
use it to demonstrate pHLIP delivery into tumor cells using systemic administration in
vivo. Our strategy is similar to the “molecular beacon", where a fluorophore-quencher
pair is used to detect nucleic acid hybridization26,

27

. In each system, fluorescence

quenching can be achieved by the close proximity of either two fluorophores (homoquenching and H-dimer formation as in the case of pHLIP-T-T) or of a fluorophorequencher pair (hetero-quenching as in the case of pHLIP-T-Q). Our approach is based
on targeting of a quenched fluorescent pHLIP-FIRE construct to acidic tumors and
activation of the fluorescence by translocating the cargo dye into cells, where the
reducing power of the cytosol triggers the enhanced fluorescence. Testing the pH
dependent interaction of pHLIP-FIRE with POPC membranes and with cultured cells
demonstrated pHLIP-like pH dependent properties and fluorescence dequenching.
When incubated with cells, the constructs showed 8- to 16-fold increase in
fluorescence with a time course of dequenching on the order of 1-2 days. These
background experiments set the stage for use in vivo.
Experiments using i.v. administration in mice resulted in the selective delivery and
activation of the pHLIP-FIREs in tumors. Biodistribution studies of pHLIP-FIREs
showed the highest accumulation in tumor sites. Slightly elevated levels of pHLIPFIRE constructs were seen in liver and kidneys compared with the control fluorescent
pHLIP construct with a single TAMRA. The activation of pHLIP-FIRE in kidneys
was expected, since the kidney is acidic, and labeling of kidneys by pHLIP has often
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been seen. The increase of fluorescence in liver most probably indicates a difference
in the biodistribution of pHLIP-FIREs compared to pHLIP-T. Because pHLIP-FIRE
constructs contain two non-polar molecules (2 TAMRA or TAMRA plus QSY9), the
increased overall hydrophobicity may facilitate liver uptake. Also, liver has the highest
concentration of glutathione in the body, which may lead to a higher rate of
dequenching 22. In contrast with the cell-free and cellular dequenching results, pHLIPT-T showed lower signal intensity compared to pHLIP-T-Q and pHLIP-T in vivo,
which we think is most probably related to the difference in pharmacokinetics of the
construct and the clearance time. Future designs may explore ways to reduce or avoid
these problems by enhancing the polarity of pHLIP-FIRE, for example by adding
polar groups to the pHLIP moiety or choosing more polar fluorophores/quenchers.
Also, use of fluorescent dyes absorbing and emitting light at longer wavelengths than
TAMRA will ensure better tissue penetration of light. However, we are mostly
concerned with proof of principle in the present study, and the most important point is
that a significant improvement in tumor-to-background ratio was achieved. A doubling
of the contrast index for pHLIP-FIREs over non-quenched pHLIP-targeted imaging
probes was observed, which allows better discrimination between healthy tissues and
tumors, and points the way for further improvements.
The pHLIP-FIRE system has potential applications in fluorescence-guided surgery and
may also have promise as a tool in cancer diagnosis. Not only have we improved the
labeling contrast, but we have also shown targeted delivery of a model cargo
(TAMRA or QSY9) into tumor cells in vivo, encouraging the further development of
pHLIP for therapeutic applications in drug delivery.

45

Methods
Chemical syntheses of pHLIP-constructs. Detailed accounts of the chemical
syntheses and characterizations of pHLIP-T, pHLIP-T-T, and pHLIP-T-Q constructs
are provided in the supplementary information. The control pHLIP-T construct was
synthesized

by

reacting

the

pHLIP-Cys

RYADWLFTTPLLLLDLALLVDADEGTC)

with

peptide

(AAEQNPIYWA-

tetramethyl-rhodamine,

6-

maleimide. The pHLIP-FIRE constructs, pHLIP-T-T and pHLIP-T-Q, were
synthesized

from

the

pHLIP-KC

peptide

(AAEQNPIYWA-RYADWLFTTP-

LLLLDLALLV-DADEGTKCG). To produce pHLIP-T-T, first the C-terminal Cys
sidechain of pHLIP-KC is derivatized as an aminoethyl disulfide. Subsequent
treatment with 5-TAMRA SE conjugates TAMRA to the primary amines of both the
Lys sidechain and the modified Cys sidechian. Synthesis of pHLIP-T-Q requires three
steps: Reaction between QSY9 succinimidyl ester and S-(2-pyridylthio)cysteamine
(step 1) provides a QSY9 derivative that is pre-activated towards disulfide exchange
with pHLIP-KC (step 2), which furnishes the C-terminal Cys sidechain with the
quencher QSY9 via a disulfide bond. Subsequent treatment of the intermediate with 5TAMRA SE (step 3) conjugates TAMRA to the neighboring Lys sidechian via an
amide bond. All intermediates and products were purified to greater than 90% purity
using HPLC and their identities confirmed by molecular mass (via MALDI-TOF mass
spectrometry to  2 dalton of expected mass).
Vesicle preparation. Large Unilammelar Vesicles (LUV) were prepared by extrusion.
A

required

stock

solution

of

POPC

(1-palmitoyl-2-oleoyl-sn-glycero-3-

phosphocholine, Avanti Polar Lipids, Inc.) in chloroform was concentrated under
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reduced pressure on a rotary evaporator and dried under vacuum overnight. The dried
lipid film was rehydrated in 10 mM phosphate buffer at pH 8.0, vortexed, and
repeatedly extruded (25 times) through a membrane with a pore size of 100 nm
(Avanti Mini-Extruder).
Chemical dequenching and Circular Dichroism measurements. Fluorescence
measurements were performed on an ISS Spectrofluorimeter. TAMRA was excited at
560 nm and fluorescence was recorded from 565 nm to 615 nm with the spectral
widths of the excitation and the emission slits at 4 nm and 8 nm respectively.
Absorbance spectra were measured on Cary 100-Bio UV-Visible Spectrophotometer.
The pHLIP-FIRE constructs were dissolved in 10 mM phosphate buffer (pH 8) at 1
µM concentration. To confirm the quenching mechanism, L-Glutathione (reduced
form, Cayman Chemical Company) was added to the construct solution to achieve the
desired final concentrations of the reducing agent (1, 3, or 10 mM). Before each
experiment glutathione powder was flushed with nitrogen and then dissolved in pH 8.0
phosphate buffer. Circular Dichroism (CD) was performed on JASCO J-810
spectropolarimeter.

Spectra were recorded at 25 ºC using a 2-mm cuvette. The

solution of 2 µM of pHLIP-FIRE in phosphate buffer (pH 8) was incubated with
POPC vesicles at the molar lipid/peptide ratio of 200:1 and kept overnight. The pH of
the samples was changed with small amounts of concentrated HCl acid.
Cell culture. Human cervix adenocarcinoma (HeLa) and human lung carcinoma
(A549) cells were obtained from the American Type Culture Collection (ATCC). An
African green monkey fibroblast-like cells, COS-7, were a kind gift from Maureen
Gilmore-Hebert and David F. Stern (Yale). The HeLa and COS-7 cells were cultured
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in DMEM supplemented with 4.5 g/L D-glucose, 10% FBS (Fetal Bovin Serum)
(Gibco) and 1% penicillin. A549 cells were cultured in DMEM at pH 6.2 for several
weeks to adjust the cells to a low pH environment. All the cells were grown in an
incubator (Revco Elite II, Thermo Fisher Scientific) under humidified atmosphere of
air and 5% CO2 at 37 ºC.
Fluorescence dequenching experiments with cells. Cells were seeded in a UV
sterilized 96-well collagen coated plate (Thermo Scientific) at a density of 5000 cells
per well, and then grown close to 100% confluency level. Then the cells were treated
with 100 µL of 1 µM of a pHLIP fluorescent construct in Dulbecco’s Phosphate
Buffer Saline (DPBS, supplied with Ca2+ and Mg2+) at pH 7.2 or pH 6.1. Incubation
was done at room temperature (22-25ºC) under normal atmosphere in the biosafety
cabinet. After 20 minutes the solution was removed and the cells were washed 3 times
with pH 7.2 or 6.1 DPBS, and finally pH 7.2 or 6.1 DMEM was added to the cells.
The pH 7.4 DMEM (no phenol red) is supplemented with 20 mM HEPES, whereas the
pH 6.1 DMEM (no phenol red) is supplemented with 20 mM HEPES and 20 mM
MES. Fluorescence was measured in a Berthold Tristar LB 941 plate reader with 535
nm excitation and 590 nm emission filters, respectively. Results obtained from five
wells were averaged for each condition. The data points were fitted using a single
exponential function with a sloped asymptotic line

,

where k is the rate constant, y is the normalized fluorescence intensity and b is the
linear component of the fluorescence signal. Cell viability was determined by adding a
small aliquot of cell titer 96 Aqueous One solution cell proliferation MTS assay
(Promega), with absorbance measured using a 490 nm filter over time. After the
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experiment, the pH of the DMEM was checked and it was found to increase no more
than 0.3 pH unit (most likely due to the bicarbonate content in the DMEM buffer
reacting with MES and/or HEPES acid).
Confocal microscopy. HeLa cells were grown in glass bottom dishes (Electron
Microscopy Science) and live cell confocal microscopy was performed on Zeiss LSM
510 NLO META using a 20X objective. Incubation times and construct concentrations
are the same as described for plate reader assays. The images were taken after 24 h of
incubation with the construct. The cells were incubated with 4 µg/mL Hoechst (Life
Technologies) 30 minutes before imaging.
Mouse experiments. BALB/c female mice ranging in age from 5 to 6 weeks were
obtained from Harlan Laboratories (Indianapolis, IN). Mouse tumors were established
by subcutaneous injection of 4T1 cells (8x105 cells/0.1 ml/flank) in the right flank of
each mouse. When tumors reached 5-6 mm in diameter, tail vein injections of 150 µL
of 25 μM of pHLIP-T-Q (5 mice), pHLIP-T-T (5 mice), or pHLIP-T (4 mice) were
performed. Animals were euthanized at 24 or 48 hours post-injections, and necropsy
was performed immediately after euthanization. Tumors and major organs were
collected for imaging on a FX Kodak in-vivo image station. Fluorescence intensity
was obtained via analysis of images by using Kodak software. The tumor/background
ratio was calculated according to the equation:

where Fltumor, Flnorm, and Flauto are the mean fluorescence intensities of tumor, muscle
and autofluorescence signal of the same organ from untreated mice, respectively.
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Figure 1. Activation of pHLIP-FIRE. State I: the peptide is soluble and unstructured
in aqueous solution at physiological pH. State II: The peptide binds to the surface of a
cell membrane in an unstructured form at physiological pH. State III: At acidic pH,
the peptide forms an α-helix and inserts across the membrane, placing the selfquencing dye construct in the reducing environment of the cytoplasm.

The

fluorescence of the dye is activated by disulfide cleavage that disrupts the
fluorophore/fluorophore or fluorophore/quencher pair, dequenching the construct and
producing strong fluorescence.
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Figure 2. Chemical dequenching of pHLIP-FIRE constructs. a) Absorbance
spectra of 1 μM pHLIP-T, pHLIP-T-Q and pHLIP-T-T before (solid line) and after
(dashed line) treatment with 10 mM of glutathione. The red-shifted peak (dashed line)
of the reduced pHLIP-T-T construct results from the conversion of H-dimer to
monomeric TAMRA. b) Fluorescence spectra of 1 μM pHLIP-T, pHLIP-T-Q and
pHLIP-T-T before (solid line) and after (dashed line) treatment with 10 mM of
glutathione. c) TAMRA fluorescence level and dequenching capacity of quenched
pHLIP-T-Q and pHLIP-T-T constructs (1 µM) and the non-quenched control pHLIP-T
(1 µM) before (gray bars) and after (red bars) the addition of 10 mM glutathione. d)
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Time-course of dequenching of pHLIP-T-Q or pHLIP-T-T (1 µM) after the addition of
1, 3, or 10 mM of glutathione. The dequenching rates are presented in Supplementary
Table 1. Error bars, s.d. (n = 3 experiments).
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Figure 3. Peptide conformations in the three states of the pHLIP-FIRE
constructs. The pHLIP-T-Q and pHLIP-T-T CD spectra. The pHLIP-FIRE peptides
were studied for the presence of the three basic states of pHLIP: state I is the peptide
in solution at pH 8 (black line), state II is the peptide in the presence of POPC
liposomes at pH 8 (blue line), and state III is the folding and insertion of the peptide
with POPC when the pH is dropped from pH 8 to pH 3.7 by the addition of an aliquot
of HCl (red line). The inserted state is monitored by changes of the CD spectral signal.
The concentrations of pHLIP constructs and POPC were 4 μM and 0.8 mM,
respectively.
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Figure 4. Changes of fluorescence intensity of TAMRA upon insertion. Insertion
of pHLIP-T-Q (a) and pHLIP-T-T (b) into HeLa and COS-7 cells at pH 6.1 (red bars)
and pH 7.4 (grey bars) at different time points are shown. Dequenching of the
fluorophore is facilitated by the highly reducing environment inside the cells. All
signals are normalized to the intensity at time zero. Error bars, s.d. (n = 6
experiments).
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Figure 5. Kinetics of dequenching of pHLIP-FIRE fluorescence resulting from
cell insertion. All data points were fitted using a single exponential function with a
sloped asymptotic line

Error bars, s.d. (n = 6

experiments).
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Figure 6. Incubation of pHLIP-FIRE with A549 cells at pH 6.1. Normalized
TAMRA fluorescence intensities of pHLIP-T (black triangle), pHLIP-T-Q (red circle),
and pHLIP-T-T (blue square). The pHLIP-T control (not quenched) showed a 2-fold
increase in fluorescence. This 2-fold background increase may be due to the partial
shielding effect of insertion into the cell or due to the different environmental
conditions inside vs. outside of the cells. Error bars, s.d. (n = 5 experiments).
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Figure 7. HeLa cells were treated with 1µM pHLIP-T-T construct for 20 min
followed by 3X DPBS washing at pH 7.4 or 6.1. TAMRA fluorescence is in red,
Hoechst fluorescence is in blue. The microscope image is taken at 24 hrs. after the
incubation. Rhodamine excitation is at 561nm.
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Figure 8. Biodistribution and contrast index of pHLIP-T-T, pHLIP-T-Q and pHLIP-T.
Fluorescent image of organs collected at 24 h (a) and 48 h (b) time after i.v. injection
of constructs. (c) Mean fluorescence values of tumor and organs are shown for pHLIPT (grey bars), pHLIP-T-Q (red bars), and pHLIP-T-T (blue bars) at 24 h and 48 h after
injection. The horizontal black line on the distribution panels indicates the level of
instrument background fluorescence. The numeric values are presented in
Supplementary Table 2. (d) Contrast indices for all constructs at 24 h time intervals:
pHLIP-T (grey bar), pHLIP-T-Q (red bar), pHLIP-T-T (blue bar). Error bars, s.e. (n =
5 mice).

p-values for pHLIP-T-Q and pHLIP-T-T are shown
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on the graph.

SUPPLEMENTARY INFORMATION
pHLIP-FIRE: a cell insertion-triggered fluorescent probe for imaging tumors
demonstrates targeted cargo delivery in vivo
Alexander G. Karabadzhak, Ming An, Lan Yao, Rachel Langenbacher, Anna
Moshnikova, Ramona-Cosmina Adochite, Oleg A. Andreev, Yana K. Reshetnyak,
Donald M. Engelman

Supplementary Description of Chemical Syntheses of pHLIP-T, pHLIP-T-T and
pHLIP-TQ Constructs.
pHLIP Peptides. The quenched pHLIP-FIRE constructs pHLIP-T-T and pHLIP-T-Q
are

synthesized

from

the

pHLIP-KC

peptide

(Acetyl-NH-

AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTKCG-CO2H). The pHLIPT

control

construct

was

synthesized

from

the

pHLIP-Cys

peptide

(AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTC). The pHLIP-C and
pHLIP-KC peptides were prepared by standard solid phase synthesis at the W. M.
Keck Foundation Biotechnology Resources Laboratory (Yale University). The Nterminus NH2 is capped with an acetyl group in pHLIP-KC. Crude pHLIP-KC peptide
was purified using high pressure/performance liquid chromatography (HPLC). The
HPLC settings are as follows: Hewlett Packard / Agilent Zorbax semi-prep 9.4 x 250
mm SB-C18 column; flow rate, 3 mL / min; phase A, water + 0.01% trifluoroacetic
acid (TFA); phase B, acetonitrile + 0.01% TFA; gradient, 30 minute from 99:1 A/B to
1:99 A/B. Under these conditions, pHLIP-KC eluted at 27:73 A/B. Unless specified
otherwise, these standard HPLC settings were also used to purify various
intermediates and pHLIP conjugates described below.
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Chemicals. 2-Aminoethanethiol (HCl salt, 98% pure) was purchased from Acros
Organics, pyridyl disulfide (98% pure) from Alfa Aesar, QSY9 succinimidyl ester
(QSY9 SE) from Life Technologies - Invitrogen - Molecular Probes, and 5carboxytetramethyl-rhodamine, succinimidyl ester (5-TAMRA SE) from AnaSpec or
Life Technologies - Invitrogen – Molecular Probes.
Instruments. HPLC was carried out using a Shimadzu system (consisting of two LC6AD liquid chromatography pumps, a DGU-20A5 Prominence degasser, a CBM-20A
Prominence communications bus module, a SPD-M20A Prominence diode array
detector, and EZstart 7.4 software for interface and data analysis). UV-vis absorbance
values (used to quantify pHLIP and pHLIP conjugates) were measured using a
Beckman DU 640 spectrophotometer and a Beckman Coulter Tm Cuvette (14 mm
high, 1 cm path length, 300 μL volume). H1 NMR was carried out on a Bruker AV
600 MHz Icon NMR. Mass spectrometry (MS) for product characterization was
carried out using the Matrix-Assisted Laser Desorption/Ionization technique coupled
with a Time of Flight mass spectrometer (MALDI-TOF). Unless specified otherwise,
all MALDI-TOF MS results were obtained by the Mass Spectrometry Laboratory at
the University of Illinois, Urbana-Champaign.

S-(2-pyridylthio)cysteamine hydrochloride. The linker S-(2-pyridylthio)cysteamine
(HCl salt) was synthesized according to the method of Ebright et al.1, with some
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modifications. A solution of 2-aminoethanethiol hydrochloride (129 mg, 1.14 mmol, 1
eq.) in methanol (1 mL) was added to a stirring solution of pyridyl disulfide (275 mg,
1.25 mmol, 1.1 eq.) in 1.2 mL of methanol and 60 μL of acetic acid in a drop wise
fashion over 10 min. The reaction mixture was stirred at r.t. under Ar in the dark for
45 min. Progress was monitored with HPLC (see above for detailed HPLC settings,
the desired product S-(2-pyridylthio)cysteamine hydrochloride eluted at 61:39 A/B
while pyridyl disulfide eluted at 25:75 A/B). The reaction mixture was concentrated
under reduced pressure several times (residue re-dissolved in methanol as needed).
The residue (or the collected precipitate) was re-dissolved in 2 mL methanol, and then
mixed with 10 mL of cold diethyl ether to precipitate the product (repeated 3 times).
The precipitate was dried under vacuum to give 95 mg of S-(2-pyridylthio)cysteamine
(38% yield) contaminated with 2- aminoethyl disulfide (HCl salt). The mother liquor
was stored at -20°C overnight to give a second batch of precipitated crystals, which
were collected via filtration, re-dissolved in 1.5 mL of methanol, and mixed with 7.5
mL of diethyl ether to precipitate out 15 mg of pure S-(2- pyridylthio)cysteamine (HCl
salt) (6% yield). 1H-NMR (DMSO-d6): δ (ppm) 3.09 (s, 4H), 7.28-7.32 (m, 1H), 7.737.76 (m, 1H), 7.82-7.87 (m, 1H), 8.10 (br s, 3H), 8.50-8.53 (m, 1H).

Synthesis of pHLIP-T-T. A solution of pHLIP-KC (1.2 mg, 0.26 μmole, 1 eq.) and S(2-pyridylthio)cysteamine hydrochloride (0.07 mg, 0.31 μmole, 1.2 eq.) in 600 μL of
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1:1 acetonitrile / aqueous (aq.) sodium phosphate buffer (100 mM, pH 8.0) was stirred
at room temperature (r.t.) under Ar for 1 hr. The progress of the reaction was
monitored by reverse phase HPLC (gradient: 99:1 A/B to 55:45 A/B over 10 min
followed by 55:45 A/B to 10:90 A/B over 35 min): pHLIP-KC eluted at 27:73 A/B,
the desired intermediate product pHLIP-KC (cysteamine disulfide) eluted at 30:70
A/B. This initial reaction is usually complete within 1h. Afterwards, a solution of 5TAMRA-SE (0.68 mg, 1.3 μmole, 5 eq.) in 400 μL of 1:1acetonitrile / water was
added and the pH of the reaction mixture was adjusted to pH 8.5 (via addition of small
amounts of aq. NaOH solution). The resulting mixture was stirred at r.t. under argon
for 3 hr. The desired final product pHLIP-T-T was isolated via HPLC (eluting at 25:75
A/B) in 69% yield (0.18 μmole) over two steps, quantified using UV absorption of Htype dimer of TAMRA at 550 nm (ε280=45,000 M-1cm-1). MALDI-TOF MS+ was
used to confirm product identity: The molecular weight (MW) calculated for pHLIPT-T (C256H352N52O68S2) is 5310, and the value obtained (using MALDI-TOF
instrument at Yale Chemistry Department core facility) is 5311.7, matching the
predicted (MW + 1) value for MH+ (molecule plus proton) of 5311.

QSY9, S-(2-pyridylthio)cysteamide. A solution of S-(2-pyridylthio)cysteamine
hydrochloride (0.24 mg, 1.08 μmole, 1.03 eq.) and triethyl amine (0.32 mg, 3.14
μmole, 3 eq.) in 0.1 mL of Ar saturated dry DMSO was used to dissolve 1 mg of
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QSY9, SE (1.05 μmole, 1 eq.). The resulting mixture was vortexed, and then allowed
to react at r.t. in the dark under Ar for 1 hr. Reaction
progress was monitored using HPLC (QSY9, SE eluted at 48:52 A/B whereas the
desired product QSY9, S-(2-pyridylthio)cysteamide eluted at 46:54 A/B). The reaction
is complete in less than one hour. Subsequently, the reaction mixture was diluted via
addition of 400 μL of dry DMSO and stored at -20°C. The desired product was
isolated using HPLC to provide 0.7 μmole of QSY9, S-(2-pyridylthio)cysteamide
(67% yield). Quantification was performed using QSY9 absorbance at 562 nm
(ε562nm in water=79,000 M-1cm-1).

pHLIP-KC(QSY9) disulfide. To a solution of QSY9, S-(2-pyridylthio)cysteamide
(655 nmole, 1.1 eq.) in 1.35 mL of Ar saturated, aq. sodium phosphate buffer (75 mM,
pH 7.8) was added a solution of pHLIP-KC (2.62 mg, 594 nmole, 1 eq.) in 100 μL of
Ar saturated DMSO. The reaction mixture was vortexed, and then allowed to react at
r.t. in the dark under Ar for 1 hr. Reaction progress was monitored using HPLC (the
desired product pHLIP-KC(QSY9) disulfide eluted at 28:72 A/B, s.m. pHLIP-KC
monomer eluted at 27:73 A/B, and pHLIP-KC disulfide dimer eluted at 24:76 A/B).
The reaction is near completion in less than 10 min. The pHLIP-KC(QSY9) disulfide
intermediate was isolated using HPLC. Collected HPLC fractions were concentrated
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under reduced pressure to remove as much acetonitrile as possible; at this point,
pHLIP conjugates often precipitated out of the acidic water (pH 3); minimal amount of
triethylamine was added to the aq. solution to adjust the pH to 7-10 and to redissolve
pHLIP; this solution was frozen and then lyophilized to give the desired product
pHLIP-KC(QSY9) in 58% yield (346 nmole), quantified using QSY9 absorbance at
562 nm (ε562nm in water=79,000 M-1cm-1). MALDI-TOF MS+ gave an observed
Exact Mass of 5282.3 (for MH+), compared with the expected Exact Mass of 5282.4
for pHLIP-KC(QSY9) disulfide (C245H345N51O70S5) plus a proton.

pHLIP-T-Q. To a solution of pHLIP-KC(QSY9) disulfide (4.3 mg, 814 nmole, 1 eq.)
and triethylamine (2.5 μL, 1.8 mg, 17.8 μmole, 22 eq.) in 400 μL of Ar saturated, dry
DMSO was added a solution of 5-TAMRA SE (0.61 mg, 1152 nmole, 1.42 eq.) in 200
μL of Ar saturated, dry DMSO. The reaction mixture was vortexed, and then allowed
to react at r.t. in the dark under Ar for 39 hr. Reaction progress was monitored using
HPLC: the desired product pHLIPK(TAMRA)C(QSY9) disulfide eluted at 25.5 : 74.5
A/B whereas 5-TAMRA SE eluted at 37:63 A/B. Since some 5-TAMRA SE
hydrolyzed over time, more 5-TAMRA SE was added at time 1hr (0.48 mg, 910
nmole, 1.1 eq., added directly) and time 24 hr (0.3 mg, 569 nmole, 0.7 eq., added as a
solution in 50 μL dry DMSO), as well as additional triethylamine at time 21 hr (1 μL,
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0.72 mg, 7.13 μmole, 8.8 eq.) and 24 hr (1.5 μL, 1.08 mg, 13.1 eq.). The final product
pHLIP-TQ was isolated via HPLC in 45% yield (362 nmole), quantified using
QSY9+TAMRA absorptions at 560 nm wavelength (ε560=79,000+83,000 M-1cm-1),
along with 48 nanomole of the recycled starting material pHLIP-KC(QSY9). MALDITOF MS+ gave observed Exact Mass of 5694.4 (for MH+) or 5733.2 (for MK+),
compared with the expected Exact Mass of 5694.5 or 5732.5 for pHLIP-T-Q
(C270H365N53O74S5) plus a proton or a potassium ion, respectively.
pHLIP-T. pHLIP-Cys was conjugated with 6-TAMRA maleimide (Invitrogen) in
DMSO at a molar ratio of 1.4:1 of dye/peptide and incubated at room temperature for
about 6 h and then at 4 °C until the conjugation reaction was complete. The reaction
progress was monitored and the desired pHLIP-Cys(TAMRA) thioether product was
purified by reverse phase HPLC. The purity of the product was assessed by analytical
HPLC.
pHLIP-FIRE dequenching rate constants in vitro and cultured cells
In vitro
pHLIP-T-T
pHLIP-T-Q

1 mM GSH
1.1 ± 0.1
0.4 ± 0.05

Cultured cells

3 mM GSH
2.7 ± 0.2
1.3 ± 0.05

10mM GSH
4.7 ±0.6
3.4 ± 0.4

HeLa
1.2 ± 0.2
0.7 ± 0.1

COS-7
1.3 ± 0.3
0.9 ± 0.1

Supplementary Table 1. pHLIP-FIRE dequenching rate constants in vitro and in
cultured cells after adding different concentrations of glutathione. Error, s.d. (n = 3
experiments for in vitro, n = 6 experiments for cultured cells).
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Mean TAMRA fluorescence with SD calculated for each organ collected at 24h or
48h.
pHLIP-T-Q

pHLIP-T

Organ

24 hours

48 hours

24 hours

48 hours

Tumor
Muscle
Liver
Kidney
Spleen
Lung
Heart

3414 ± 369
668 ± 55
1826 ± 195
2895 ± 194
433 ± 21
656 ± 68
407 ± 41

1672 ± 109
546 ± 22
1452 ± 140
856 ± 76
331 ± 13
641 ± 19
374 ± 4

2648 ± 261
752 ± 24
1131 ± 85
801 ± 67
339 ± 19
564 ± 51
350 ± 12

1226 ± 41
562 ± 22
658 ± 44
495 ± 25
352 ± 41
479 ± 22
363 ± 15

pHLIP-T-T
24 hours

48 hours

1586 ± 70
1077 ± 141
552 ± 7
491 ± 19
1064 ± 136 716 ± 60
997 ± 68
541 ± 29
347 ± 13
303 ± 10
542 ± 56
583 ± 27
343 ± 25
336 ± 14

Supplementary Table 2. Numeric fluorescence values of each organ. Errors, s.d. (n =
5 mice).
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Abstract
Tumor development, progression, and invasiveness are associated with the elevation
of acidosis. The most effective pH-sensitive tumor targeting agents should sense pH at
the surface of cancer cells, where it is expected to be the lowest. We have designed,
synthesized, and evaluated a series of cyclic pH-sensitive peptides containing a
number of tryptophan (W) and glutamic acid (E) residues. Biophysical studies
revealed the molecular mechanism of peptides action and localization within the lipid
bilayer at high and low pHs. Fluorescently-labeled peptides were tested for targeting
of acidic tumors in mice. The highest tumor to muscle ratio (4.3) was established for
an asymmetric cyclic peptide, c[E4W5C], at 4 h after intravenous administration. The
same asymmetric cyclic peptide can translocate polar cargo molecules of similar size
across lipid bilayer in a pH- and concentration-dependent manner. We introduced a
novel class of pH-sensitive agents, cyclic peptides, which could be developed for
imaging of acidity in tumors and translocation of polar cargo molecules across the
lipid bilayer of the membrane. These data suggest that cyclic peptides containing
tryptophan and glutamic acid can be utilized as a new class of pH-sensitive cellular
delivery and tumor targeting tools.
Extracellular acidity is associated with various pathological states, such as tumor,
ischemia, stroke, and infection. There are a number of approaches under development
for delivery of imaging and therapeutic agents to diseased tissue in a pH-dependent
manner. They are based on the use of pH-sensitive polymers, liposomes, nanoparticles
and small molecules.[1-7] Among peptides, family of pHLIPs, linear peptides of 25-35
residues, which insert into cellular membrane and form transmembrane helices are
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used for targeting of acidic tumors of various origins and other acidic diseased
tissues.[8,9]
Application of cyclic peptides in biological sciences has become a subject of major
interest because of their enhanced enzymatic stability versus linear peptides.[10]
Recently we reported the design and synthesis of homochiral L-cyclic peptides
containing arginine (R), tryptophan (W) residues and their application for the nuclear
targeting delivery of anti-HIV drugs, phosphopeptides, anticancer drugs, and
siRNA.[11-14] These peptides offered several advantages including nuclear delivery of
doxorubicin, endocytosis-independent uptake, low cytotoxicity, biocompatibility,
hydrophobic drug entrapment through non-covalent interactions, and drug delivery
through conjugation with doxorubicin.
Here we design pH-sensitive negatively charged cyclic peptides and study their
interactions with the lipid bilayer of liposomal and cellular membranes in vitro and in
vivo. To the best of our knowledge, this is the first report of using pH-sensitive cyclic
peptides for intracellular delivery of a toxin and tumor targeting.
We introduced and investigated one linear and five cyclic peptides (Figure 1 and Table
S1). All peptides contain: i) single cysteine (Cys, C) residue for conjugation purposes,
ii) at least one tryptophan (Trp, W) for ability to record fluorescence signal, iii) 3-5
protonatable glutamic acid (Glu) residues to trigger pH-dependent interaction with
membrane. First three peptides, c[(WE)4WC], c[(WE)5WC], and c[(WE)3WC] have 3,
4, and 5 repeating units of WE, respectively, where Trp and Glu residues are
alternating in the cyclic peptide. Another peptide, c[(LE)4WC], has leucine (Leu, L)
instead of Trp to investigate the role of aromatic Trp residues for peptides interaction
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with the membrane. Fifth peptide, c[E4W5C], is an asymmetric; it has five Trp
residues located on one side of the cycle, while four Glu residues are located on the
other side of the cycle. Finally, we synthesized also linear l(CW(EW)4) 10-residues
peptide for the comparison with the cyclic peptides.
The peptides were synthesized by employing Fmoc/tBu-based solid phase chemistry.
As representative examples, the synthesis of l(CW(EW)4 and c[(WE)4CW] peptides
are depicted in Scheme S1. In brief, the linear protected peptide was first assembled.
Direct cleavage of peptide-attached resin generated the linear peptide. However,
cleavage of side chain protecting groups from the resin in the presence of
AcOH/TFE/DCM (1:2:7 v/v/v), cyclization in dilute condition using DIC/HOAt in
DMF/DCM solution for 12 h, followed by the deprotection of the side chain by using
cleavage cocktail (TFA:thioanisole:anisole:EDT (90:5:2:3 v/v/v/v) afforded the cyclic
peptide. All peptides were purified by reverse phase HPLC.
The fluorescent techniques were employed to establish the molecular mechanism of
peptides interaction with membrane and their localization within the lipid bilayer at
high and low pHs. We monitored changes of tryptophan fluorescence (Figure S1,
Table S2) and circular dichroism (Figure S2) spectral signals for the peptides in
absence and presence of POPC liposomes at different pHs. All peptides demonstrated
pH-dependent partition into the membrane. Asymmetric cyclic peptide with Trp
residues located on one side of the cycle, c[E4W5C], most probably partitions into the
membrane facing Trp residues inside a bilayer and exposing Glu to the extracellular
space. The drop of pH leads to the protonation of carboxyl groups of Glu residues,
which increases peptides hydrophobicity and promotes partition of peptides in bilayer.
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As a result, positions of maximum of fluorescence spectra shift to 6-9 nm to short
wavelengths (Figure 2 and Table S2). The linear peptide shows appearance of helicity
in the result of pH drop (Figure S2). c[(WE)4WC], c[(WE)5WC] and c[(WE)3WC]
peptides show similar CD signals at pH 8, which are altered by interaction with lipid
bilayer and drop of pH. The CD signal of c[E4W5C] peptide was different but was also
pH-dependent. We did not observe characteristic CD signal of exiton with a minimum
at 232-235 nm. Such an exciton might be formed as the result of the stacking of
aromatic amino acids due to peptides aggregation/stacking.[18] Thus, we concluded that
at concentrations of the peptides we used in our study, it is unlikely formation of some
kind tubular structures of peptides.
To establish localization of the peptides within a lipid bilayer of the membrane, dual
quenching assay[15] was used (Figure 2 and Table S3). Effective quenching of
fluorescence by acrylamide would occur only for tryptophan residues exposed to polar
parts of outer or inner leaflets of the bilayer. At the same time, tryptophan residues
located in the middle of a membrane would be effectively quenched by 10-DN. The
c[E4W5C] demonstrates the highest quenching by 10-DN and highest energy transfer
at pH 8 indicating to the internal position of Trp residues in the bilayer of the
membrane. All other peptides are located at the outer leaflet of the bilayer at pH 8.
The peptides c[(WE)3WC] and c[(LE)4WC] are the most exposed to the aqueous
solution showing the highest degree of quenching by acrylamide and least quenching
by 10-DN. The peptide c[(LE)4WC] might be less exposed, while it’s single Trp could
be oriented toward aqueous solution, while Leu residues are located deeper in the
membrane.
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The results of dual quenching assay allow to establish if tryptophan residues are
located in the middle of a membrane or close to the polar headgroups of bilayer.
However, it would not allow distinguishing between location at outer or inner leaflets
of the bilayer. Therefore, we also performed FRET assay (Figure 3).[16,17] First,
symmetrically-labeled by NBD dye POPC liposomes were prepared. Then,
membrane-impermeable dithionite was used to modify chemically and quench
fluorescence of NBD at outer leaflet of the bilayer followed by removal of dithionite
by gel filtration. As a result, asymmetrically-labeled liposomes with NBD only at the
inner leaflet were obtained. FRET is monitored from tryptophan residues to NBD,
which occurs when both fluorophores are in a proximity to each other (within 5-15 Å).
Thus, when tryptophan is located at outer leaflet of the bilayer, no significant energy
transfer to NBD at inner leaflet would occur (the distance will be about 50-60 Å). The
energy transfer would be detected only if tryptophan residues were located in the
middle of the membrane or at inner leaflet. FRET signal would be maximal, when
tryptophan is located in proximity to the headgroups of the inner leaflet. Among
c[(WE)4WC], c[(WE)5WC], and c[(WE)3WC] peptides, the peptide with smallest
cycle, c[(WE)3WC], shows the deeper partition into membrane and closer location to
the inner leaflet, since FRET signal is the highest for it. The highest partition into
bilayer at pH 3 is observed for asymmetric c[E4W5C] peptide. Linear peptide,
l(CW(EW)4), also demonstrates partition into bilayer in the result of pH drop.
By monitoring shift of the position of maximum of fluorescence spectra for the
peptides in the result of pH drop, we established apparent pK of peptides partition into
bilayer. The pKa for most cyclic and linear peptides varies in the range of 5.7-6.4,
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while the smallest pKa value is observed for cyclic Leu-containing peptide,
c[(LE)4WC] (Figure 4).
Extracellular acidity is established already at early stages of tumor development,
during the avascular phase of carcinoma in situ. As tumor continues to grow, acidosis
is increasing due to the poor blood perfusion, switch of cancer cells to glycolytic
mechanism of energy production even in the presence of oxygen and overexpression
of carbonic anhydrases (CA). Adaptations to the highly acidic microenvironment are
critical steps in the transition from an avascular pre-invasive tumor to a malignant
invasive carcinoma.[25-28] Thus, targeting of tumor acidity might serve as a predictive
marker for tumor invasiveness. pH is especially lower in the vicinity of the membrane
of cancer cells due to the work of proton pumps and CAIX and CAXII. Also, pK of
protonation of Asp and Glu residues is higher (pK6-7) near the surface of the
hydrophobic membrane compared to bulk aqueous solution, where pK3-4.[29-32] The
protonation of Asp/Glu in the range of pHs of 6-7 established for cyclic peptides is
relevant to tumor environment, where pH is about 6.2-6.8.
Before animal studies, we showed no cytotoxicity induced by peptides (Figure S3).
Next we proceed to in vivo tumor targeting experiments. The murine 4T1 xenograft
model, which closely mimics stage IV of human breast cancer[19-21] was used in our
study. Small 4T1 tumor (tumor volume <150 mm3) generates a significant level of
lactate and serve as a good model of an aggressive, acidic tumor.[22] All peptides were
covalently conjugated with Alexa546-malemiede. The fluorescent constructs were
given as a single IV injection and at 4 h after administration animals were euthanized
followed by necropsy. The mean fluorescence of tumor, muscle, kidney, liver and
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lungs were recorded and analysed. The highest tumor targeting was observed for linear
peptide, l(CW(EW)4), and asymmetric cyclic peptide, c[E4W5C] (Figure 5a, b and
Table S4). The least targeting was observed for Leu-containing peptide, c(LE)4CW.
The signal in organs for all peptides except Leu-containing peptide was smaller than in
tumor. Muscle clearance was also highest for linear, l(CW(EW)4), and asymmetric
cyclic, c[E4W5C], peptides (Figure 5c and Table S5). We exclude the possibility of
passive tumor targeting by peptides, since it should be very similar for all peptides, or
at least for symmetric and asymmetric peptides of the exact the same molecular
weights and compositions. Also at time point of 4 h after constructs administration the
clearance of organs (muscle, liver, lungs) is very significant, thus the signal in tumor
cannot be attributed to the presence of the peptides in blood.
According to obtained data, the linear peptide belongs to the class of truncated pHLIP
peptides, which form a helical structure in the membrane in a result of pH drop. Linear
peptide we investigated here has 10 amino acids, which is a minimal number for the
formation alpha and/or 310 helices or mixture of both to span bilayer, with the
assumption of some thinning of bilayer, as we established in other our study of
truncated pHLIP peptides (paper is in preparation). Linear pHLIPs indeed show
excellent tumor targeting since it is based on a pH-dependent membrane-associated
folding with well controlled pKa of peptides insertion into bilayer. Among cyclic
peptides, the best tumor targeting was established for asymmetric peptide, which we
investigated further.
Asymmetric cyclic peptide was evaluated for its ability to move polar cargo across
membrane. As a polar cargo we used amanitin, which is a cell-impermeable cyclic
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peptide. It is a deadly toxin, which inhibits RNA polymerase II, if transferred across
lipid bilayer of plasma membrane. The pH- and concentration-dependent cell death
was observed after treatment of HeLa cells with up to 4 µM of c[E4W5C]-S-SAmanitin (see Scheme S2, for the peptide-amanitin structures) for just 2 hours (Figure
6). The similar results were obtained with c[(WE)4WC]-S-S-Amanitin (Figure S4).
Previously we showed that amanitin alone does not induce cell death at the
concentrations used and for the duration of treatment of 2 hours.[23] We also tested
construct, where amanitin was conjugated to the asymmetric c[E4W5C] cyclic peptide
via non-cleavable bond (Scheme S2, b). The cytotoxic effect for non-cleavable
construct was reduced significantly at both pHs (Figure 6). It might indicate that the
equilibrium is shifted toward peptide membrane-bound form, and cleavage of amanitin
from the peptide is needed to allow amanitin to reach RNA polymerase II in the
nucleus. Alternatively, if peptide-amanitin is translocated into cytoplasm, the cleavage
of amanitin might be required, since affinity of the peptide-amanitin to the RNA
polymerase II might be reduced compared to the affinity of free amanitin to the RNA
polymerase II. Based on the obtained results, we proposed that at high/normal pH
asymmetric cyclic peptide is mostly located at the outer leaflet of the bilayer. In the
result of pH drop, protonation of Glu residues leads to the enhancement of peptide
hydrophobicity and partition into bilayer, where it is mostly concentrated on inner
leaflet, since Glu residues could be de-protonated in cytoplasm of cells. This
assumption was further confirmed by quenching of fluorescence of FITC labeled with
asymmetric cyclic peptide by cell impermeable Trypan Blue (Figure S5). Trypan Blue
is used to quench fluorescence of FITC located in the extracellular space.[24] Our data
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indicate that cells treated with the FITC-labeled peptide at low pH followed by Trypan
Blue quenching show higher level of fluorescent signal compared to the cells treated
with the FITC-labeled peptide at normal pH followed by Trypan Blue quenching
(Figure S5).
Targeting of membrane by asymmetric cyclic peptide, c[E4W5C], has a different
mechanism compared to the action of linear peptides. Our data indicate that negatively
charged Glu residues of asymmetric cyclic peptide are exposed to the aqueous solution
at pH 8. Trp residues most probably do not partition deep into the membrane (Figure 7
and Figure S6). It is known that indole rings of Trp residues can stably interact with
the interface between bilayer lipid chains and headgroups.[31,33-36] When pH is lowered,
Glu residues are protonated. The pKa of protonation is higher due to the proximity to
hydrophobic membrane.[29-32] Protonation leads to the increase of hydrophobicity of
the peptide, which promotes partition of the peptide into bilayer. However, due to the
fact that Trp residues have higher affinity to the headgroups region compared to the
central hydrophobic part of bilayer, peptide is equilibrated in the region of headgroups
between inner and outer leaflets of bilayer. We and others showed that pH equilibrates
fast inside a liposome.[32,37] Thus, an equal amount of the peptide molecules are
distributed between both leaflets of liposomal membrane with low pH outside and
inside of it (Figure S6). However, in the case of cells, pH inside both normal and
cancer cell is normal (around 7.2). At the same time, extracellular pH in the vicinity of
cancer cells is low (6.2-6.5). As a result, peptides reaching inner leaflet of the bilayer
might expose their Glu residues to the cytoplasm, where they would be de-protonated
and became charged again. It would reduce the rate of the peptide diffusion back into
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the membrane and should lead to the shift of the equilibrium toward accumulation of
the peptides at inner leaflet of bilayer of plasma membrane of cells (Figure 7). Thus,
the cyclic peptide could be considered as a weak acid with multiple protonated groups,
which diffuses across bilayer. For weak acids, the intracellular-extracellular
distribution, Ci/Ce, should be calculated according to the following equation:

where pHi and pHe are the intracellular and extracellular pH values, respectively.
Since the cyclic peptide has affinity to the membrane we consider Ci and Ce as the
concentrations of the peptide on inner and outer leaflets, respectively. We established
that pKa of membrane partition for asymmetric cyclic peptide is 5.7. The calculation
show that at pHe = 7.4 (healthy tissue) and pHi = 7.2 the concentration ratio on inner
and outer leaflets for asymmetric cyclic peptides is 0.6. However, the same ratio
increases to 4.5, 7.8, and 10.9 if extracellular pHe would be 6.5, 6.2 and 6.0,
respectively.
We assume that the symmetrical WE peptides have the same mechanism of action as
asymmetric peptide, however they have less favorable localization of Trp and Glu
residues, which reduces their ability to accumulate at inner leaflet of bilayer of cellular
membranes and target acidic tumors. Leu-containing peptides are less advantageous
due to their reduced affinity to the headgroup part of the bilayer and high affinity to
the center of the membrane.
Our study justifies further development and testing of pH-sensitive asymmetric cyclic
peptides for imaging of acidic tumors. Cyclic peptides have much higher stability in
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blood compared to linear peptides and could have much faster blood clearance, which
will be very advantageous for clinical imaging.

Keywords: amanitin •dual-quenching assay • fluorescence spectroscopy • microscopy
and imaging • NBD-FRET assay • Trypan • Blue quenching
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Figure 1. Chemical structures of cyclic peptides.
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Figure 2. Quenching of fluorescence of peptides in the presence of POPC liposomes
at pH 8 (blue lines) or at pH 3 (red lines) by acrylamide (green lines) and 10-DN
(magenta lines) are shown. The percentage of quenching is given in Table S3.
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Figure 3. NBD fluorescence spectra of peptides in phosphate buffer at pH 8 (black
lines) and in presence of asymmetrically labeled POPC liposomes containing NBD at
inner leaflet at pH 8 (blue lines) and at pH 3 (red lines) are shown. The numbers
indicate an increase of FRET at pH 3 compared to the peptide fluorescence in
phosphate buffer at pH 8.
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Figure 4. The changes of tryptophan fluorescence are used to follow the partition of
the peptides into POPC liposomes as a function of pH. Fitting curve (red lines) and
95% confidence interval (blue lines) are shown.
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Figure 5. Ex vivo fluorescence imaging of tumor, muscle, lungs, liver and kidneys
collected at 4 h after IV administration of Alexa546-peptides (a); values of mean
fluorescence of organs with St.d. (b) and Tumor/organ ratios (c) are shown. The
values are given in Tables S4 and S5 of Supplementary Materials.
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Figure 6. Concentration- and pH-dependent inhibition of HeLa cells proliferation was
monitored at 48 h after incubation of cells with cleavable asymmetric c[E4W5C]-S-Samanitin and non-cleavable c[E4W5C]-amanitin constructs for 2 h at normal (pH 7.4)
and low (pH 6.2) pHs followed by constructs removal and keeping cells in DMEM
with 10% FBS at pH 7.4. The total number of points averaged for each concentration
is six.
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Figure 7. The peptides distribution between outer and inner leaflet of the lipid bilayer
of plasma membrane. At neutral and high pHs, Glu residues are negatively-charged
(red circles). Trp residues (green circles) interact with polar headgroups. Cys residue
(yellow circle) could be directed into bilayer or away depending on hydrophobic or
hydrophilic cargo is conjugated with it. More cyclic peptides could be found on the
outer bilayer of plasma membranes of cells compared to the inner bilayer due to the
small pH gradient (pHe = 7.4 and pHi = 7.2). Drop of a pH leads to the protonation of
Glu residues (blue circles), which enhances peptides hydrophobicity and induces
partition into bilayer.
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SUPPORTING INFORMATION
pH-Sensitive Cyclic Peptides for Tumor Targeting
Dhammika Weerakkody,a Anna Moshnikova,a Naglaa Salem El-Sayed,b,c,d, RamonaCosmina Adochite,a Jovana Golijanin,a Rakesh K. Tiwari,b,c,d Oleg A. Andreev,a
Keykavous Parang,b,c,d,* Yana K. Reshetnyaka,*

EXPERIMENTAL SECTION
1. Peptide Synthesis
1.1. Materials. The peptide synthesis materials including Fmoc-L-amino acid building
blocks, preloaded amino acids on 2-chlorotrityl resin as the solid support, and 2(1H−benzotriazol-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate

(HBTU)

used for coupling reagents were purchased from Chem-Impex Int’l Inc., Wood Dale,
IL. Piperidine and N-methylmorpholine were purchased from Sigma-Aldrich
Chemical

Co.

(Milwaukee,

WI).

The

other

chemicals

such

as

N,N-

diisopropylethylamine (DIPEA), cleavage cocktail reagents trifluoroacetic acid (TFA),
1-hydroxy-7-azabenzotriazole (HOAt), N,N'-diisopropylcarbodiimide (DIC), acetic
acid (AcOH), 2,2,2-trifluoroethanol (TFE), anisole, thioanisole, ethanedithiol (EDT),
and anhydrous solvents such as N,N-dimethylformamide (DMF), dichloromethane
(DCM), hexane, acetic acid (AcOH), and 2,2,2-trifluoroethanol (TFE) were purchased
from Fisher Scientific, Pittsburg, PA.
1.2. Methodology. The peptides were synthesized by employing the N-(9fluorenyl)methoxycarbonyl (Fmoc)-solid phase chemistry using PS3 automated
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peptide synthesizer (Rainin Instrument Co., Inc.) at room temperature. The peptide
sequence was assembled on preloaded amino acid on 2-chlorotriyl resin using
coupling, activating, and deprotecting reagents using HBTU, N-methylmorpholine
(0.4 M), and piperidine in DMF (20% v/v), respectively. The amino acids in the
peptide sequence were coupled using coupling reagents and activating reagent in DMF
for 1 h followed by washing with DMF 3 times. The deprotection were carried using
piperidine (20%, v/v) in DMF for 2 times, 10 minute for each time, followed by
washing with DMF (3 times). The appropriate sequence of linear protected peptide
was assembled using the synthesizer. N- to C-terminal cyclization of peptide were
achieved by cleavage of protected peptidyl resin by stirring the peptidyl resin in
freshly prepared cleavage cocktail of AcOH/ TFE/DCM (1:2:7, v/v/v) for 1 h at room
temperature followed by washing the resin with TFE:DCM (2:8 v/v, 2 times). The
collected filtrate was evaporated using a rotary evaporator followed by azeotropic
removal of acetic acid by addition of hexane and dichloromethane to afford high
viscous liquid or solid-protected linear peptide. The crude linear protected peptide was
dissolved in excess of solvents DMF:DCM (4:1 v/v) followed by the addition of
HOAt/DIC (1:1.1 equiv) for cyclization for 12-48 h confirmed by MALDI TOF-TOF
mass spectrometry. The solvent was evaporated under high reduced pressure in a
rotatory evaporator at 40-45 oC to remove DMF. The final cleavage of side chain
protection from the peptide were carried out after confirming the peptide cyclization
by MALDI mass spectrometer data by shaking the cyclized peptide mixture in
cleavage cocktail reagent R (TFA/thioanisole/anisole/EDT (90:5:2:3 v/v/v/v, 10-15
mL) for 2-4 h followed by precipitation of peptide using cold ether, centrifugation at
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2500 rpm and washing with excess of cold ether at 25 oC for 5 min. The crude peptide
was purified with semi preparative reversed phase high performance liquid
chromatography (RP-HPLC) by using Hitachi L-2455 on a C18 Phenomenex Prodigy
reversed-phase column (10 μm, 250 cm x 21.2 cm). The pure peptide was eluted at
15.0 mL/min using a gradient of binary solvent system using water and acetonitrile
with 0.1% TFA for 0-100% over 60 min. The pure collected peptide fractions were
pooled and lyophilized to provide solid powder in purity of ≥98 %. All peptides were
characterized by using high resolution time of flight AXIMA-performance MALDI
TOF-TOF mass spectrometer (Shimadzu). The above mentioned protocol was applied
for the synthesis of all cyclic peptides. As representative examples, the synthesis of
cyclic, c[(WE)4CW], and linear, l(CW(EW)4), peptides is described here and provided
in Scheme S1, respectively.
1.2.1. Synthesis of c[(WE)4CW]. The linear peptide sequence was synthesized on
PS3 automated synthesizer as described above in the scale of 0.3 mmol. H-Trp(Boc)2-chlorotrityl resin (384.6 mg, 0.3 mmol, 0.78 mmol/g) was swelled in DMF, followed
by coupling and deprotection cycles to assemble respective amino acids on the
peptidyl resin using respective amino acids, such as Fmoc-Glu(OtBu)-OH (382.9 mg,
0.9 mmol), Fmoc-Trp(Boc)-OH (473.9 mg, 0.9 mmol), Fmoc-Cys(Trt)-OH (527.1 mg,
0.9 mmol), and HBTU ( 341 mg, 0.9 mmol) as the coupling reagent (Scheme S1).
Fmoc group of N-terminal in the peptidyl resin was removed using deprotection cycle,
and the resin was transferred to 100 ml round bottom flask. The linear protected
peptide was cleaved by shaking peptidyl resin in cleavage cocktail AcOH/TFE/ DCM
(1:2:7 v/v/v, 50 ml) for 1 h followed by washing the resin using TFE:DCM (2:8 v/v,
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10 mL, 2 times). The combined filtrate was evaporated to dryness with the
subsequently addition of hexane (50 mL × 3) and DCM (10 mL × 3) to remove acetic
acid, which provided solid white crude protected peptide ready for cyclization. The
cyclization was carried out by dissolving the solid peptide in anhydrous DMF/DCM
(250 mL, 4:1 v/v) under nitrogen using DIC (155.0 μL, 0.99 mmol) and HOAt (122.5
mg, 0.9 mmol) with stirring at room temperature for 24 h. The cyclized product was
confirmed by taking small aliquot of the reaction mixture and cleavage with reagent R
and using MALDI. After cyclization was confirmed, the solvents were evaporated
under high reduced pressure, and the side chain protections were removed by addition
of cleavage cocktail of reagent R, TFA/thioanisole/anisole/EDT (15 mL, 90:5:2:3
v/v/v/v), and shaking at room temperature for 3 h. The peptide was precipitated,
centrifuged, and washed with cold diethyl ether to yield the crude white solid peptide.
The peptide was dissolved in H2O/ CH3CN with 0.1% TFA and purified using RP
HPLC. Then, the pure fractions were collected, concentrated and lyophilized to afford
pure

solid

white

powder

of

c[(WE)4WC]

peptide.

MALDI-TOF

(m/z)

[C78H83N15O18S]: calcd, 1549.5761; found, 1572.2693 [M + Na ]+; c[(WE)5WC]:
MALDI-TOF (m/z) [C94H100N18O22S]: calcd, 1864.6980; found, 1865.3943 [M + H]+;
c[(WE)3WC]: MALDI-TOF (m/z) [C62H66N12O14S]: calcd, 1234.4542; found,
1234.7385

[M]+;

1257.5951;

found, 1258.2421 [M

c[(LE)4WC]:

MALDI-TOF

(m/z)

[C58H87N11O18S]:

+ H]+; c[E4W5C]:

calcd,

MALDI-TOF (m/z)

[C78H83N15O18S]: calcd, 1549.5761; found, 1549.1430 [M]+.
1.2.2. Synthesis of l(CW(EW)4). The linear peptide was assembled as described
above using H-Trp(Boc)-2-chlorotrityl resin (384.6 mg, 0.3 mmol 0.78 mmol/g) in
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reaction vessel (Scheme S1). The peptide sequence was assembled using the
appropriate amino acid building blocks Fmoc-Glu(OtBu)-OH (382.9 mg, 0.9 mmol),
Fmoc-Trp(Boc)-OH (473.9 mg, 0.9 mmol), Fmoc-Cys(Trt)-OH ( 527.1 mg, 0.9
mmol), and HBTU (0.9 mmol, 341 mg) as the coupling reagent. The final N-terminal
Fmoc group was deprotected. The peptide was cleaved from the resin and side chain
was deprotected by reaction of the peptidyl resin with freshly prepared cleavage
cocktail reagent R, TFA/thioanisole/anisole/EDT (15 mL, 90:5:2:3 v/v/v/v), for 3 h at
room temperature. The linear protected peptide was precipitated, centrifuged, and
purified by using RP-HPLC as mentioned above to yield l(CW(EW)4). MALDI-TOF
(m/z) [C78H85N15O19S]: calcd, 1567.5867; found, 1606.1204 [M + K]+.
Concentration of peptides was calculated spectrophotometrically by measuring
absorbance at 280 nm. The extinction coefficients, ε280, M−1 cm−1, for the peptides are
the following: c[(WE)4WC] = 28,000; c[(WE)5WC] = 33,600; c[(WE)3WC] = 2,400;
c[(LE)4WC] = 5,600; c[E4W5C] = 28,000; l(CW(EW)4) = 28,000.
1.2.3. Labeling of Peptides with Fluorescent Dyes. Peptides were conjugated with
Alexa546- and Fluorescein-5-maleimide (Life Technologies) in DMF at a ratio of
1.2:1 and incubated at room temperature for about 6 hours and then at 4 °C until the
conjugation reaction was completed. 50 mM of sodium phosphate /150 mM NaCl
buffer pH7.0 (saturated with argon) was added to the reaction mixture (1/10 of the
total volume). The reaction progress was monitored by the reverse phase HPLC. The
products were purified by the reverse phase HPLC, lyophilized and characterized by
SELDI-TOF mass spectrometry. The concentration of the constructs was determined
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by absorbance at 556 and 494 nm using molar extinction coefficients of 93,000
M−1·cm−1 for Alexa546 and 68,000 M−1·cm−1 for Fluorescein-5 (FITC).
1.2.4. Synthesis of Peptide-Amanitin Constructs. We conjugated symmetric
c[(WE)4WC] and asymmetric c[E4W5C] peptides with alpha-amanitin (SigmaAldrich) via cleavable S-S bond. Furthermore, asymmetric c[E4W5C] peptide was
labeled with amanitin via non-cleavable bond. The conjugation Scheme consists of 2
steps: i) NH2 group of amanitin (see Scheme S2, a) was conjugated with NHS group
of the cleavable crosslinker, SPDP, N-succinimidyl 3-(2-pyridyl-dithio)-propionate
(Scheme S2, b) or the non-cleavable crosslinker, GMBS, N--maleimidobutyryloxysuccinimide ester (Scheme S2, c) (both crosslinkers were from (Thermo Scientific)
in 50 mM sodium phosphate/150 mM NaCl buffer pH 7.6 at a ratio 1:20 at room
temperature for 4 h to get SPDP-amanitin or GMBS-amanitin. The products were
purified by the reverse phase HPLC on Zorbax SB-C18 column (9.4 x 250mm, 5Micron). SPDP-amanitin was eluted using a gradient: 0-25%, 40 min (water and
acetonitrile with 0.05% TFA) and lyophilized. c[(WE)4WC] and c[E4W5C] peptides
were incubated with SPDP-amanitin or GMBS-amanitin in 100 mM sodium
phosphate/150 mM NaCl buffer pH 7.8 (saturated with argon) at a ratio 1:1 at room
temperature for 1 h to obtain amanitin-SPDP-peptides (Scheme S2, d and f) or
amanitin-GMBS-peptide (Scheme S2, e), respectively. The products were purified by
the reverse phase HPLC on Zorbax SB-C18 column (9.4 x 250mm, 5-Micron) using
gradient 10-55%, 40 min (water and acetonitrile with 0.05% TFA). The products were
lyophilized and characterized by SELDI-TOF mass-spectrometry. The calculated and
obtained masses for the peptides are the following: c[E4W5C]-SPDP-amanitin:
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SELDI-TOF (m/z) [C120H139N25O33S3]: calcd, 2553.9129; found 2555.5263 [M + H]+;
c[E4W5C]-GMBS-amanitin: SELDI-TOF (m/z) [C125H144N26O35S2]: calcd, 2632.9279;
found 2634.5723 [M + H]+, and 2657.8214 [M + Na]+; c[(WE)4WC]-SPDP-amanitin:
SELDI-TOF (m/z) [C120H139N25O33S3]: calcd, 2553.9129; found 2554.5000 [M + 1]+.
2. Liposome Preparation. Large unilamellar vesicles (LUVs) were prepared by
extrusion. POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (Avanti Polar
Lipids), or a mixture of POPC with 0.5% of 18:1 NBD-PE, 1,2-dioleoyl-sn-glycero-3phosphoethanolamine-N-7-nitro-2-1,3-benzoxadiazol-4-yl ammonium salt (Avanti
Polar Lipids) were dissolved in chloroform, desolvated on a rotary evaporator, and
dried under high vacuum for several hours. The phospholipid film was then rehydrated
in 10 mM phosphate buffer pH 8.0, vortexed until the lipid bilayer was completely
dissolved, and repeatedly (15-21 times) extruded through the membranes with 50 nm
pore sizes to obtain LUVs.
3. Steady-State Fluorescence and CD. Freshly prepared peptides and POPC vesicles
were mixed to have 5 M of a peptide and 1.25 mM of lipids in the final solution.
Steady-state fluorescence measurements were carried out on a PC1 spectrofluorometer
(ISS, Inc.) under temperature control at 25 C. Tryptophan fluorescence was excited at
280 nm (there is no Phe or Tyr in the peptides) and recorded with the excitation and
emission slits set at 1 nm. The polarizers in the excitation and emission paths were set
at the “magic” angle (54.7o from the vertical orientation) and vertically (0o),
respectively. Steady state CD measurements were carried out in MOS 450
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spectropolarimeter (Bio-Logic, Inc.) with the same concentrations of peptide and
lipids as it were used in fluorescence measurements.
4. pH-Dependence. pH-dependent partitioning of the peptides into a lipid bilayer of
membrane was investigated by the shift of the position of the fluorescence spectral
maximum for the peptides in the presence POPC liposomes induced by a drop of pH
from 8 to 2.5 by addition of HCl. The peptides were incubated overnight with 50-nm
POPC liposomes (final concentration of the peptides and POPC in solution was 5 μM
and 1 mM, respectively), and pH decrease was achieved by the addition of aliquots of
4, 2, 1 and 0.1 M HCl. pH was measured by micro-electrode probe (Thermo Electron
Corporation, Orion Ross Micro pH electrode). Fluorescence spectra were recorded at
each pH value. The spectra were analyzed by the decomposition algorithms using online

PFAST

toolkit

(Protein

Fluorescence

and

Structural

Toolkit:

http://pfast.phys.uri.edu/) to establish the position of the emission maximum. Finally,
the positions of the fluorescence spectral maxima (max) were plotted versus pH, and
the Henderson–Hasselbalch equation was used to fit the data (using Origin 8.5
software):

where

and

are the beginning and end of the transition, and pKa – is the

midpoint of the transition.
5. Dual Quenching. POPC liposomes without and with 10% of the lipids replaced by
10-doxylnonadecane (10-DN) (Avanti Polar Lipids) were prepared in 10 mM citrate101

phosphate buffer pH 8.0. Peptides and POPC liposomes were mixed to generate final
concentrations of 7 M peptide and 2.1 mM POPC without and with 10-DN. In some
of the samples, the pH was lowered to pH 4 by addition of aliquot of 2 M citric acid,
and other samples were kept at pH 8. To the samples of POPC liposomes containing
no 10-DN, acrylamide (Sigma-Aldrich) was added to have a final concentration of 235
mM in solution. Concentration of peptides in all samples was kept constant. To
observe quenching of tryptophan fluorescence by 10-DN or acrylamide, the
tryptophan fluorescence was recorded as described above. The appropriate POPC
blanks were measured and subtracted from the measured spectra before analysis. The
percentage of quenching was calculated.
6. NBD-FRET. First, symmetrically NBD-labeled POPC liposomes containing 0.5%
of NBD-PE were prepared. Next, 1.2 ml of 6 mM of symmetrically NBD-labeled
POPC liposomes were incubated with 150 l of 1 M freshly prepared membraneimpermeable dithionite in buffer at pH 8.0 to chemically deactivate of NDB only at
outer leaflet of bilayer and obtain asymmetrically NBD-labeled POPC liposomes. The
decrease of NBD fluorescence occurring in the result of quenching of NBD by
dithionite was monitored at excitation of 463 nm and emission at 530 nm. The
dithionite quenching leads to the reduction of about 60-65% of NBD fluorescence
signal corresponding to the NBD on the outer leaflet of the bilayer. Next, POPC
solution was passed through a G-10 sephadex (Sigma-Aldrich) column to remove the
excess of dithionite. Asymmetrically labeled POPC liposomes were incubated with
peptides at concentrations indicated above, and FRET from tryptophan residues to
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NBD at inner leaflet of bilayer was monitored at 280 nm excitation wavelength, and
emission was recorded from 310 to 580 nm.
7. Cell Lines. Human cervix adenocarcinoma (HeLa) cells were acquired from the
American Type Culture Collection. Cells were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10
μg/mL of ciprofloxacin in a humidified atmosphere of 5% CO2 and 95% air at 37°C.
The pH 6.2 medium was prepared by mixing 13.3 g of dry DMEM with 0.15 g of
sodium bicarbonate in 1 L of deionized water.
8. Cytotoxic Assay. HeLa cells were loaded in the wells of 96-well plates (~5,000
cells per well) and incubated overnight. Growth medium was replaced with the
medium without FBS pH 6.2 or pH 7.4 containing increasing amounts of constructs
(5, 10, 20, and 40 μM). The same volume of DMEM medium supplemented with 20%
FBS, pH 7.4 was added after 2 h of treatment. After 48 h of incubation a colorimetric
reagent (CellTiter 96 AQueous One Solution Assay, Promega) was added for 1 h
followed by measuring absorbance at 490 nm to assess cell viability. All samples were
prepared in triplicate.
9. Proliferation Assay. HeLa cells were loaded in the wells of 96-well plates (~5,000
cells per well) and incubated overnight. Growth medium was replaced with the
medium without FBS pH 6.15 or pH 7.4 containing increasing amounts of peptideamanitin construct (0.5, 1, 2, and 4 μM). The construct was removed after 2 h. After
48 h of incubation in standard growth medium, a colorimetric reagent (CellTiter 96
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AQueous One Solution Assay, Promega) was added for 1 h followed by measuring
absorbance at 490 nm to assess cell viability. All samples were prepared in triplicate.
10. Fluorescent Microscopy. HeLa cells (8,000 cells per dish) were seeded in the
center of a 35-mm dish with a 10-mm glass-bottom window coated with collagen
(MatTek Corp). Next day cells were incubated with 5 µM of FITC-labeled c[E4W5C]
peptide for 30 min in DMEM medium without FBS at pH 7.4 or 6.2. Cells were
washed 5 times at pH 7.4 and 0.4% Trypan Blue was added for 5 min (1/10 of the total
volume). Fluorescent images were acquired with a Retiga CCD camera (Qimaging)
mounted to an inverted Olympus IX71 microscope (Olympus America, Inc.).
11. Ex Vivo Fluorescence Imaging. All animal studies were conducted according to
the animal protocol AN04-12-011 approved by the Institutional Animal Care and Use
Committee at the University of Rhode Island, in compliance with the principles and
procedures outlined by NIH for the Care and Use of Animals. 4T1 breast tumors were
established by subcutaneous injection of 4T1 cells (8 × 105 cells/0.1 mL/flank) in the
right flank of adult female BALB/c mice (about 19-22 g weight) obtained from Harlan
Laboratories. When tumors reached about 6 mm in diameter single tail vein injections
of 100 µl of 40 µM Alexa546-peptides were performed. Control mice bearing tumor
used to establish an auto fluorescence signal did not receive fluorescent peptides. At 4
h post-injection euthanization and necropsy was performed followed by ex vivo
imaging of tumor, kidneys, liver, lungs and muscle. Mean fluorescence intensity of
tumor and organs was calculated using Kodak software.
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TABLES
Table S1. Properties of the synthesized peptides.
Peptide

Calculated
M.W.

Found M.W.

Retention
time in
HPLC

%
purity

c[(WE)4WC]

1549.5761

1572.2693 [M + Na
]+

35.2-36.7

99

c[(WE)5WC]

1864.6980

1865.3943 [M +H]+

35.8-37.2

99

c[(WE)3WC]

1234.4542

1234.7385 [M]+

35.0-36.0

99

c[(LE)4WC]

1257.5951

1258.2421 [M + H]+

35.2-36.3

95

c[E4W5C]

1549.5761

1549.1430 [M]+

36.6-37.7

99

l(CW(EW)4)

1567.5867

1606.1204 [M + K]+

32.3-33.2

99
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Table S2. The spectral parameters of the peptides in phosphate buffer at pH 8, in the
presence of POPC liposomes at pH 8 and pH 3 are presented. The parameters were
obtained from analysis of the fluorescence spectra shown in Figure 2: the maximum
position of the fluorescence spectrum max, in nm; S – the normalized area under the
spectra (normalization was done on the area under the spectrum for peptides at pH 8 in
absence of POPC liposomes, black lines on Figure 2).

max, nm
Peptide

S

Pep, pH8

Pep-PC,
pH8

Pep-PC,
pH3

Pep-PC,
pH8

Pep-PC,
pH3

c[(WE)4WC]

350.5±0.2

347.5±1.2

341.1±0.9

1.1±0.1

1.6±0.2

c[(WE)5WC]

350.3±0.2

346.7±1.2

341.2±0.4

1.5±0.3

2.1±0.3

c[(WE)3WC]

351.0±0.2

349.1±0.7

341.7±0.2

0.9±0.1

1.7±0.3

c[(LE)4WC]

348.7±0.3

348.2±0.6

339.6±1.2

1.1±0.0

1.1±0.1

c[E4W5C]

350.6±0.2

342.8±0.4

340.2±0.4

2.4±0.3

2.4±0.5

l(CW(EW)4)

353.0±0.7

346.6±0.7

339.8±0.6

2.3±0.4

1.6±0.4
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Table S3. The percentage of peptides fluorescence quenching by addition of
acrylamide (AC) or 10-DN at pH 8 and pH 3 in the presence of POPC liposomes are
shown. The values were obtained from analysis of the fluorescence spectra shown in
Figure 3.
Pep-PC+AC
pH8

Pep-PC+
10-DN pH8

PepPC+AC
pH3

Pep-PC+
10-DN pH3

c[(WE)4WC]

82

11

50

40

c[(WE)5WC]

78

13

68

40

c[(WE)3WC]

83

6

63

47

c[(LE)4WC]

96

0

59

17

c[E4W5C]

61

49

54

52

l(CW(EW)4)

81

20

56

31
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Table S4. Mean NIR fluorescence with standard deviation calculated for each organ
collected at 4 h after Alexa546-peptide administration. The data are shown on Figure
6b.

Al546c[(WE)4WC]
Al546c[(WE)5WC]
Al546c[(WE)3WC]
Al546c[(LE)4WC]
Al546c[E4W5C]
Al546l(CW(EW)4)

Tumor

Muscle

Liver

Kidney

Lungs

2459.1±552.3

850.6±27.9

1235.9±206.5

711.3±212.6

427.7±39.7

1621.6±422.1

626.5±84.4

710.4±122.5

705.7±260.4

403.1±43.7

2066.2±486.5

706.7±107.1

1150.5±314

704.4±205.1

416.6±35.5

1380±193.7

453.3±53.8

370.6±65.7

2039.0±1080.7

279.1±47.7

3204.8±1011.7

745.9±55.5

825.1±130.5

996.2±160.8

429.4±93.5

4426.8±214.5

936.5±52.1

1323.9±478.4

1891.9±756.5

522.9±42.4

Table S5. Tumor/Organ ratios calculated based on the data presented in Table S1. The
data are shown on Figure 6c.

Tumor/Muscle Tumor/Liver Tumor/Kidney Tumor/Lung
Al546c[(WE)4WC]
Al546c[(WE)5WC]
Al546c[(WE)3WC]
Al546c[(LE)4WC]
Al546-c[E4W5C]
Al546l(CW(EW)4)

2.91±0.73

2.04±0.61

3.51±0.3

5.70±0.83

2.56±0.36

2.26±0.31

2.39±0.54

3.98±0.69

2.94±0.63

1.85±0.48

3.04±0.85

5.02±1.4

3.05±0.36

3.76±0.4

0.88±0.58

5.02±0.96

4.25±1.09

3.95±1.38

3.27±1.21

7.48±2.14

4.73±0.31

3.80±1.88

2.68±1.34

8.52±1.00
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Schemes

Scheme S1. Synthesis of l(CW(EW)4) and c[(WE)4CW] peptides.
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Scheme S2. Structures of amanitin (a), SPDP (b) and GMBS (c) crosslinkers.
Schematic presentation of structures of c[E4W5C] peptide conjugated with alphaamanitin via cleavable S-S (d) and non-cleavable (e) bonds using SPDP and GMBS
crosslinkers, respectively, (f) c[(WE)4WC]-SPDP-amanitin conjugated with alphaamanitin via cleavable S-S bond using SPDP linker.
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Figures

Figure S1. The emission of peptides in phosphate buffer at pH 8 (black lines) and in
the presence of POPC liposomes at pH 8 (blue lines) and pH 3 (red lines) are shown.
The spectral parameters are given in Table S2.
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Figure S2. The circular dichroism of peptides in phosphate buffer at pH 8 (black line)
and in presence of POPC liposomes at pH 8 (blue line) and pH 3 (red line) are shown.
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Figure S3. HeLa cells were treated with increasing concentrations of peptides without
FBS at pH 6.2 (red lines and circles) or pH 7.4 (black lines and circles). The same
volume of DMEM medium supplemented with 20% FBS, pH 7.4 was added after 2
hrs of treatment. After 48 hours of incubation MTS assay was performed to access cell
viability.
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Figure S4. Concentration- and pH-dependent inhibition of HeLa cells proliferation
was monitored at 48 h after incubation of cells with cleavable c[(WE)4WC]-S-SAmanitin construct for 2 hours at normal (pH 7.4) and low (pH 6.2) pHs followed by
constructs removal and keeping cells in DMEM with 10% FBS at pH 7.4. The total
number of points averaged for each concentration is six.

Figure S5. FITC-labeled asymmetric cyclic peptide, c[E4W5C], was treated with cells
for 30 min at pH 7.4 or 6.2, followed by washing at pH 7.4 in both cases, addition of
Trypan Blue for 5 min and live cell imaging. Cells treated with FITC-peptide at low
pH, washed at normal pH and incubated with Trypan Blue show higher level of
fluorescence signal compared to the cells treated with FITC-peptide at normal pH,
washed at normal pH, and incubated with Trypan Blue.
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Figure S6. The peptides distribution between outer and inner leaflet of the lipid
bilayer in liposomes. At neutral and high pHs, Glu residues are negatively-charged
(red circles). Trp residues (green circles) interact with polar headgroups. Cys residue
(yellow circle) could be directed into bilayer or away depending on hydrophobic or
hydrophilic cargo is conjugated with it. Drop of a pH leads to the protonation of Glu
residues (blue circles), which enhances peptides hydrophobicity and induces partition
into bilayer. In the case of liposomes, pH equilibrates fast, thus low pH will be outside
and inside of liposome. It would lead to the equilibration of concentration of cyclic
peptides with protonated Glu residues between inner and outer leaflets of the bilayer.
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ABSTRACT
An enhanced use of glycolysis and production of carbonic and lactic acids, actively
contribute to the extracellular acidosis, promoting tumor development, progression
and invasiveness. Thus, extracellular acidity might serve as a general marker for
detection and targeting of aggressive tumors. pH (Low) Insertion Peptides (pHLIPs)
pertain to the class of pH-sensitive agents able of sensing pH at the cellular surface
and delivery of imaging and/or therapeutic agents to the cancer cells in tumors. Here,
we investigated targeting of highly metastatic 4T1 mammary carcinoma and
biodistribution of different pHLIP variants conjugated with various fluorescent dyes
with the main purpose to identify the best pHLIP-based constructs for clinical
applications. All fluorescent pHLIPs exhibited good targeting of breast tumors with
minimal accumulation in muscle at 24 hours post-injection. The highest tumor
targeting with low accumulation in liver, kidney and muscle was observed for
Alexa546-pHLIPs. Also, we showed that Alexa546-Var3 targets 500 m sized
metastatic lesions in lungs. Fluorescent pHLIP-based agents could be used for
diagnosis and treatment (surgical resection) of primary tumors and submillimeter
metastatic lesions.
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Introduction
A common specific feature of tumor microenvironment is a hypoxia and an
extracellular acidosis 1. The acidification of extracellular space leads to reverse of a
pH transmembrane gradient in cancer cells

2,3

. Previous research showed that the

acidic extracellular pH, promotes invasion and metastasis of cancer cells

4,5

. The

highly proliferative cancer cells (metabolically active cells) are the most acidic. Thus,
targeting of tumor acidity might be developed as an important predictive clinical
marker of tumor aggressiveness and invasiveness. However, a sharp proton
concentration gradient exists near the surface of cancer cells. Thus, the best approach
will be to access acidity in close proximity to cancer cells in tumors.
We have introduced family of pH Low Insertion Peptides (pHLIPs), which represents
a unique class of water-soluble membrane polypeptides capable to undergo a pHdependent membrane-associated folding

6,7

. pHLIP peptides possess dual delivery

capabilities, making use of the energy of folding to translocate polar cargo molecules
across phospholipid bilayer of membrane and/or tether molecules to the cell surface 8.
Also, the process of peptide folding within a membrane ensures a high cooperativity
of the transition, which cannot be achieved by simple diffusion

9,10,11

. Since pHLIPs

are in equilibrium between membrane bound and non-bound configurations at normal
pH they are capable of sensing pH at the cell surface. As soon as pH drops (even on a
half of pH unit), the Asp and Glu residues are protonated enhancing affinity of
peptides to membrane, which triggers folding in membrane and release of energy.
Depending on pHLIP sequence protonatable residues could be differently located on
membrane surface, which directly affects the rate of the protonation events at various
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pHs, and thus pK of peptides insertion into the membrane. We have introduced family
of pHLIP peptides with pK of insertion varying from 4.5 to 6.5 and confirmed that
tumor targeting is indeed pH-dependent 5,7. Three pHLIP variants, WT, Var3 and Va7
were selected as lead candidates for pH-specific delivery of imaging and therapeutic
agents to tumors of different origins 7. We showed previously targeting of tumors by
fluorescently-labeled WT-, Var3- and Var7-pHLIP as well by the pHLIP-Fluorescence
Insertion REporter (pHLIP-FIRE)

12,13,14

. One of the very attractive potential clinical

applications of fluorescent pHLIPs might be a fluorescence-guided surgical resection
of tumors. The proliferative cancer cells will light up most of all targeted by the
fluorescent-pHLIPs. However, in addition to the peptide sequence variation,
fluorescent dyes (which are usually about one third of pHLIP peptides mass) can
affect and alter tumor targeting and biodistribution of pHLIPs. In the present study, we
compared targeting of mammary tumors and biodistribution

of different pHLIP

variants conjugated with eight fluorescent dyes with the main purpose to identify the
best pHLIP-based constructs for various clinical uses. Also, we demonstrated staining
of sub-millimeter metastatic lesions in lungs by Alexa546-Var3.
Materials and Methods
Conjugation of pHLIP peptides with fluorescent dyes
pHLIP variants were prepared by solid-phase peptide synthesis using Fmoc (9fluorenylmethyloxycarbonyl) chemistry and purified by reverse phase chromatography
by CS Bio. pHLIP variants were conjugated with Alexa546-, Alexa647-, Alexa750-,
Cy5.5-, Dy680-, DyP680-maleimide (Life Technologies) and IR680-, IR800maleimide (LiCor Biosciences) in DMF (dimethylformamide) at a ratio of 1:1 and
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incubated at room temperature for about 8 hours and then at 4ºC until the conjugation
was completed. The reaction progress and purity was monitored by reverse phase
HPLC to ensure absence of free dyes in the final solution. The products were
lyophilized and characterized by SELDI-TOF mass spectrometry. The concentration
of constructs was determined by absorbance using the following molar extinction
coefficients: 556=104,000 M−1·cm−1 (for Alexa546-pHLIPs), 650=239,000 M−1·cm−1
(for Alexa647-pHLIPs), 753=290,000 M−1·cm−1 (for Alexa750-pHLIPs), 673=209,000
M−1·cm−1 (for Cy5.5-pHLIPs), 672=165,000 M−1·cm−1 (for IR680-pHLIPs),

778=300,000 M−1·cm−1 (for IR800-pHLIPs), 684=140,000 M−1·cm−1 (for Dy680pHLIPs) and 684=180,000 M−1·cm−1 (for DyP680-pHLIPs).
Absorption and fluorescence measurements
Absorbance and fluorescence measurements were carried out on a Genesys 10S UVVis (Thermo Scientific) spectrophotometer and a SpectraMax M2 (Molecular
Devices) spectrofluorometer, respectively. The excitation wavelengths were the
following for different constructs: 550 nm for Alexa546-pHLIPs; 650 nm for
Alexa647-pHLIPs, 673 nm for Cy5.5-pHLIPs; 680 nm for IR680-pHLIPs, Dy680pHLIPs and DyP680-pHLIPs; 750 nm for Alexa750-pHLIPs and 780 nm for IR800pHLIPs.
Cell lines
The 4T1 and 4T1-GFP mouse mammary tumor cell lines were obtained from the
American Type Culture Collection and cultured in RPMI medium supplemented with
10% fetal bovine serum, 10 μg/mL of ciprofloxacin in a humidified atmosphere of 5%
CO2 and 95% air at 37°C.
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Tumor mouse models
Mammary tumors were established by subcutaneous injection of 4T1 cells (8x105
cells/0.1 ml/flank) in the right flank of adult female BALB/c mice (about 19-22 g
weight) obtained from Harlan Laboratories. For the metastatic tumor model, 1x 106
4T1-GFP cells/50 l were injected subcutaneously in the mammary fat pad. After
approximately 3 weeks, the primary tumor metastasized in the lungs. All animal
studies were conducted according to the animal protocol AN04-12-011 approved by
the Institutional Animal Care and Use Committee at the University of Rhode Island, in
compliance with the principles and procedures outlined by NIH for the Care and Use
of Animals.
Fluorescent imaging of organs and tissue
When tumors reached approximately 5-6 mm in diameter tail vein injections of 100
L of 40 M of fluorescent-pHLIPs were performed. Animals were euthanized at 2, 4,
24 and 48 hours post-injection, and necropsy was performed immediately after
euthanization. Tumors and major organs of BALB/c mice were collected for imaging
on a FX Kodak in-vivo image station. Fluorescence intensity was obtained via analysis
of images by using Kodak software. The contrast index (CI) was calculated according
to the equation:

where Ftumor , Fmuscle and Fbackg are the mean fluorescence intensities of tumor, muscle
and background signal of the same organ from untreated mice, respectively.
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Fluorescent images of metastatic lesions in lungs were acquired at 4 and 10x
magnification using an Olympus IX71 inverted fluorescence microscope.
Results
The focus of our work was targeting of mammary tumors by three pHLIP variants
recently selected for pre-clinical development 7,10:
WT: ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT
Var3: ACDDQNPWRAYLDLLFPTDTLLLDLLW
Var7: ACEEQNPWARYLEWLFPTETLLLEL
Each peptide had a single Cys residue at the N-terminus for conjugation with
fluorescent dyes. We used fluorophores emitting at visible and near-infrared
wavelengths: Alexa546, Alexa647, Alexa750, Cy5.5, Dy680, DyP680, IR680, IR800
(see Table 1). The molecular weights and HPLC retention times, reflecting the
hydrophobicity of the investigated fluorescent constructs, are also given in Table 1.
The absorption and emission spectra of fluorescent constructs are shown in
Supplementary Figure 1. The fluorescence was measured in absence and presence of
POPC liposomes to mimic behavior of the fluorescent constructs in membraneunbound and membrane-bound forms.
With the selected fluorescent dye, Alexa750, we also investigated performance of the
following pHLIP sequences, where the N-terminal end of the peptides contains six
negatively-charged Asp residues for the enhancement of constructs solubility:
Var3M: ACDDDDDDPWQAYLDLLFPTDTLLLDLLW
Var7M: ACDDDDDDPWQAYLDLFPTDTLALDLW
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In addition we studied biodistribution of the constructs, where Alexa546 and Cy5.5
fluorescent dyes were attached to the single Cys residue at the membrane-inserting Cterminus of the Var3 pHLIP peptide:
Var3-C: ADDQNPWRAYLDLLFPTDTLLLDLLCW
To test tumor targeting by fluorescent pHLIPs we selected the highly tumorigenic and
invasive 4T1 mammary carcinoma model, which mimics stage IV of human breast
cancer

33-35

, and is known to be acidic

13

and targeted very well by pHLIPs

10

. This

transplantable cancer cell line can spontaneously metastasize from the primary tumor
in the mammary gland to multiple distant sites

15,16

. Fluorescent pHLIPs were

administrated intravenously and at different time points ranging from 2 to 48 hours,
animals were euthanized, tumor, kidney, liver and muscle were collected and imaged
immediately. The representative fluorescent images of tissue and organs obtained at 4
hours after the constructs administration are shown on Figure 1. Very good tumor
targeting was observed by all fluorescent-PHLIPs. The fluorescent images obtained at
different time points were used to calculate changes of the mean surface fluorescence
intensity in tissue and organs (Figure 2 and Supplementary Table 1), tumor to organ
ratios (Figure 3 and Supplementary Table 2) and contract index (CI) (Figures 4 and
Supplementary Table 3).
Different fluorescent pHLIPs demonstrate different kinetic profiles (Figure 2 and
Supplementary Table 1). The highest tumor targeting was observed at 2 or 4 hours
post-injection with subsequent decay of the signal. Most fluorescent pHLIPs have low
liver accumulation except of Cy5.5-pHLIPs, which are the most hydrophobic
construct among the investigated. We also performed study with Cy7.5-Var3, which is
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more hydrophpobic, and observed significant liver accumulation (data not shown).
Surprisingly, Alexa546-pHLIPs, which are second the most hydrophobic constructs
after Cy5.5-pHLIPs, showed very low liver, kidney and muscle accumulation with the
highest tumor targeting. Tumor to muscle ratio for Alexa546-Var3 was increasing
from ~ 5 to 9 within 24 hrs (Figure 3 and Supplementary Table 2). With the shift to
near infrared (NIR) wavelengths of excitation and emission for Alexa647-, IR680- and
Dy680-pHLIPs more kidney targeting was monitored. Alexa750- and IR800-pHLIPs
demonstrate the highest signal in the kidney and liver. We compared performance of
Dy680 and its pegylated version, DyP680. The DyP680-pHLIPs are more polar
compared to Dy680-pHLIPs.

The most noticeable difference was observed in

targeting of the kidney: DyP680-pHLIPs demonstrate about twice higher accumulation
in the kidney than Dy680-pHLIPs, which could be related to the renal clearance. In
overall the contrast index was enhanced for pegylated versions of the constructs
compared to non-pegylated counterparts (Figure 4 and Supplementary Table 3).
The contrast index was calculated only for two time points, 2 and 4 hours, since
fluorescent signal in muscle at 24 and 48 hrs post-injection was at the level of the
background fluorescence (Figure 4 and Supplementary Table 3). We did not observe
any significant difference between various pHLIP sequences, except of Alexa546Var3, which showed statistically significant higher CI compared to Alexa546-WT and
– Var7. The highest contrast (around 6) was observed for Alexa546-, Dy680- and
DyP680 at 2 hrs post-injection. At 4 hrs the highest contrast of >8 was found for
Cy5.5-pHLIPs. The lowest CI was detected for IR680-pHLIPs.
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We tested ability of pHLIPs to deliver imaging agents into the cell by conjugating
Alexa546 and Cy5.5 dyes to the C-terminal part of Var3 peptide, which inserts into
the lipid bilayer of membrane. We selected the most hydrophobic dyes to avoid
complications with their translocation across cellular membrane. Our data indicate that
CI was very similar for the constructs, where Alexa546 or Cy5.5 were conjugated to
the N- or C-terminus. We can conclude that pHLIP is capable of delivering of imaging
agents not only to the cell surface but also across membrane into a cell. However, the
polarity of imaging agent will affect the process of its cellular delivery. Also, we
evaluated performance of modified Var3M and Var7M, where several Asp residues
were inserted at the N-terminus of the peptides. The statistically significant
improvement was observed only for Alexa750-Var7M compared to Alexa750-Var7.
The Alexa546-Var3 construct was selected for testing of targeting of submillimeter
metastatic lesions in lungs. Since 4T1 cells implanted into mice have stable expression
of GFP the lesions were identified by GFP fluorescence on the excised fresh lungs
tissue by fluorescence microscopy (Figure 5). The GFP signal has excellent colocalization with Alexa546-Var3 fluorescent indicating that 400-500 m sized
metastatic lesions are acidic and targeted by fluorescent pHLIP.
Discussion
The approach for targeting of tumors, which we develop, is based on the marking of
tumor acidity associated with tumor development, progression, aggressiveness and
invasiveness. We have shown previously, that peptides of pHLIP family deliver
optical, PET and SPECT imaging agents to the primary tumors and metastatic lesions
in a pH-dependent manner

10,17,18

. Here we carried out a systematic investigation of
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targeting of 4T1 mammary tumors, kidney, liver and muscle at different time points
after single intravenous administration of various pHLIPs conjugated with eight
different fluorescent dyes. Since the most NIR fluorescent dyes are large cyclic
molecules (about 1 kDa in mass) they can affect and alter biodistribution of pHLIPs
(about 4 kDa in mass). All fluorescent pHLIPs show slow tumor targeting, which
ranged within hours after constructs administration. It is advantageous for drug
delivery, since it could enhance pHLIP-drug circulation in blood. The best tumor
targeting was observed for pHLIP variants (WT, Var3 and Var7) conjugated with
Alexa546 at both N- or C-termini of the peptides to tether dye to the membrane of
cancer cells in the extracellular or intracellular spaces, respectively. Accumulation of
the Alexa546-pHLIPs in other organs and tissue was about 4 times less than in tumor.
Thus, Alexa546 potentially can alter biodistribution of pHLIPs in a favorable way, and
might be used with pHLIP-drug constructs. According to our data, Var3 demonstrates
the highest tumor targeting in the most cases. We also showed targeting of
submillimeter metastatic lesions in lungs by Alexa546-Var3, which opens opportunity
of imaging and treating of metastasis employing pHLIP-technology.
The fluorescent pHLIPs also could have important implication for staining and
visualization of cancer cells during surgical procedures

19

. Fluorescence -guided

surgery has the promise to improve surgical procedures by determining tumor margins
using tumor-specific targeting and by increasing the visual information available to the
surgeon 20. This technique, can possibly lead to complete resection of the tumor tissue
with improved survival. On the foundation of the hallmarks of cancer, there is a
variety of tumor-specific agents that are available for imaging of cancer
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21

. To obtain

target-specific fluorescence imaging, the contrast agent has to be sent to the tumor site,
and has to be kept by the target while nonbound agents are cleared from the circulation
17,22

. Mostly, NIR dyes are suited better for tissue staining, since auto fluorescence

signal in NIR is much lower compared to visible light.

The biodistribution is less

critical, however the highest possible contrast between cancerous and normal tissue is
the key. Var3 conjugated either with N- or C-terminus with Alexa546 or Cy5.5 show
the highest tumor accumulation and highest contrast between tumor and normal tissue.
Among NIR dyes, Alexa750, IR800 or Dy680 and DyP680 might be used for surgical
procedures.
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FIGURE LEGENDS
Figure 1. Distribution of the fluorescent pHLIPs in 4T1 mammary tumors (cut in
half), muscle, kidney and liver. Fluorescent images of tissue and organs were
obtained at 4 hrs after single i.v. administration of WT, Var3 and Var7 peptides
conjugated with fluorescent dyes.
Figure 2. Time-dependent distribution of the fluorescent-pHLIPs in 4T1
mammary tumors, kidney, liver and muscle quantified by the ex-vivo mean
fluorescence. The data in each row were normalized to the intensity in tumor of the
corresponding fluorescent-WT at 2 hours. The numeric values of non-normalized
fluorescent intensities are presented in the Supplementary Table 1.
Figure 3. Tumor to organ ratios calculated for 2, 4 and 24 hrs time points. The
numeric values of tumor to organ ratios are presented in the Supplementary Table 2.
Figure 4. Contrast index (CI) calculated at 2 and 4 hrs time points. The p-level
values were computed based on the two-tailed test. The numeric values of CI are
presented in the Supplementary Table 3.
Figure 5. Targeting of submillimeter metastatic lesions in lungs. 4T1-GFP cells
were injected subcutaneously in the mammary pad of the mouse. After 3 weeks, the
primary tumor metastasized in the lungs. The Alexa546-Var3 was given as a single
i.v. tail vein injection. At 4 hrs post-injection animals were euthanized, the lungs were
excised and imaged immediately on the fluorescent microscope.
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Tables
Table 1. Spectral properties (position of maximum of absorbance, ab, and emission,
em), molecular weights and HPLC retention times of the fluorescent-pHLIP
constructs are shown.
Spectral Properties

ab,
nm
em,
nm

Al546

Al647

Al750

Cy5.5

IR680

IR800

Dy680

DyP680

556

650

753

630/673

672

778

680

680

572

670

778

720

702

797

707

707

Molecular Weights
WT

5146

5362

5462

4853

5140

5303

5084

5866

Var3

4256

4472

4572

3963

4250

4413

4194

4976

Var7

4100

4316

4416

3807

4094

4257

4038

4820

Var3C

4313

-

-

4020

-

-

-

-

HPLC Retention Times
WT

29.2

24.8

25.3

29.4

25.5

25.0

26.2

24.9

Var3

27.6

23.3

23.6

28.4

24.3

23.4

25.0

23.7

Var7

25.7

21.6

22.0

26.9

22.8

21.6

23.9

22.0

Var3C

27.5

-

-

29.8

-

-

-

-
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Figure 1. Distribution of the fluorescent pHLIPs in 4T1 mammary tumors (cut in
half), muscle, kidney and liver. Fluorescent images of tissue and organs were
obtained at 4 hrs after single i.v. administration of WT, Var3 and Var7 peptides
conjugated with fluorescent dyes.
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Figure 2. Time-dependent distribution of the fluorescent-pHLIPs in 4T1
mammary tumors, kidney, liver and muscle quantified by the ex-vivo mean
134

fluorescence. The data in each row were normalized to the intensity in tumor of the
corresponding fluorescent-WT at 2 hours. The numeric values of non-normalized
fluorescent intensities are presented in the Supplementary Table 1.
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Figure 3. Tumor to organ ratios calculated for 2, 4 and 24 hrs time points. The
numeric values of tumor to organ ratios are presented in the Supplementary Table 2.
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Figure 4. Contrast index (CI) calculated at 2 and 4 hrs time points. The p-level
values were computed based on the two-tailed test. The numeric values of CI are
presented in the Supplementary Table 3.
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Figure 5. Targeting of submillimeter metastatic lesions in lungs. 4T1-GFP cells
were injected subcutaneously in the mammary pad of the mouse. After 3 weeks, the
primary tumor metastasized in the lungs. The Alexa546-Var3 was given as a single
i.v. tail vein injection. At 4 hrs post-injection animals were euthanized, the lungs were
excised and imaged immediately on the fluorescent microscope.
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SUPPLEMENTARY DATA
Comparative study of tumor targeting and biodistribution of pH (Low) Insertion
Peptides conjugated with various fluorescent dyes
Ramona-Cosmina Adochite1, Anna Moshnikova1, Jovana Golijanin1, Oleg A.
Andreev1, Yana K. Reshetnyak1,*

Table S1. Mean surface fluorescence obtained from the organs and tissue at different
time points after single i.v. administration of the fluorescent constructs. Values for the
control represent baseline autofluorescence signal from animals with no injection of
fluorescent constructs. The number of animals for each time point and each construct
is indicated by n.
Alexa546-pHLIPs

Organs

Muscle

Tumor

Liver

Kidney

Time
postinjection
2 hrs
4 hrs
24 hrs
48 hrs
2 hrs
4 hrs
24 hrs
48 hrs
2 hrs
4 hrs
24 hrs
48 hrs
2 hrs
4 hrs
24 hrs
48 hrs

WT
n=6

Var3
n=6

Var3-C
n=3

Var7
n=6

1057.0 ±137.8
1212.0 ± 189.4
249.4 ± 23.2
193.6 ± 18.0
3856.7 ± 1058.5
5716.8 ± 1284.8
1287 ± 290.4
999.5 ± 129.8
1671.7 ± 148.7
1984.0 ± 27.9
502.5 ± 85.6
357.2 ± 24.6
1235.5 ± 182.2
1099.2 ± 254.3
544.8 ± 85.9
485.4 ± 126.5

963.4 ± 120.8
1117.9 ± 167.3
297.7 ± 28.6
201.0 ± 13.3
4664.5 ± 720.4
5809.9 ± 880.4
2772.9 ± 600.3
1229.6 ± 281.9
1670.3 ± 409.5
1448.7 ± 317.7
303.4 ± 64.4
254.9 ± 37.2
880.3 ± 51.2
1148.4 ± 326.7
1288.7 ± 253.3
918.5 ± 225.9

281.6 ± 23.3
283.8 ± 52.6
209.5 ± 18.6

1150.2 ± 126.6
756.9 ± 34.9
191.2 ± 8.34
179.4 ±16.1
3267.1 ± 690.0
3514.1 ± 622.9
810.4 ± 196.2
516.7 ± 128.9
805.8 ± 112.4
623.6 ± 77.2
217.0 ± 21.8
193 ± 20.6
1346.8 ± 145.8
1045.2 ± 144.4
821.3 ± 122.5
690.5 ± 259.6

834.6 ± 86.6
847.3 ± 162.2
1168.5 ± 299.8
380.3 ± 39.2
288.4 ± 11.8
229.5 ± 17.6
326.8 ± 83.1
327.7 ± 41.3
291.9 ± 17.9

Control

156.3

170.2

144.2

156.4

Alexa647-pHLIPs

Organs

Time
postinjection

WT
n=3

Var3
n=3
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Var7
n=3

Control

Muscle

Tumor

Liver

Kidney

2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs

2617.5 ± 616.0
2093.2 ± 111.4
932.8 ± 49.0
7498.5 ± 1480.5
6798.8 ± 221.9
2480.1 ± 290.3
5311.2 ± 97.9
5137.2 ± 1330.5
1680.4 ± 490.3
8516.0 ± 1611.7
9135.8 ± 1167.8
3778.7 ± 550.7

4940.6 ± 527.6
3467.6 ± 839.4
1054.8 ± 121.0
14565.3 ± 1577.3
12099.6 ±255.7
3948.6 ± 2212.7
9832.4 ± 622.3
7615.7 ± 1028.3
1327.4 ± 298.0
16126.9 ± 2787.4
14325.3 ± 1332.3
6081.2 ± 2036.8

1818.8 ± 200.0
1569.0 ± 275.9
1016.0 ± 171.7
6556.0 ± 1013.2
4781.5 ± 675.1
2832.5 ± 588.2
2598.1 ± 335.6
1921.6 ± 351.0
1091.4 ± 175.4
10112.8 ± 391.6
10696.1 ± 1726.5
8461.9 ± 4773.8

980.7

1125.5

525.6

552.6

Alexa750-pHLIPs

Organs

Muscle

Tumor

Liver

Kidney

Time
postinjection
2 hrs
4 hrs
24 hrs
48 hrs
2 hrs
4 hrs
24 hrs
48 hrs
2 hrs
4 hrs
24 hrs
48 hrs
2 hrs
4 hrs
24 hrs
48 hrs

WT
n=3

Var3
n=3

Var7
n=3

889.8 ± 87.2
700.2 ± 117.8
275.5 ± 10.1
168.7 ± 7.3
2847.7 ± 40.1
2897.5 ± 610.4
1118.9 ± 76.5
414.6 ± 23.7
3577.2 ± 375.5
3776.3 ± 1111.3
1370.9 ± 104.7
363.1 ± 36.6
7413.1 ± 881.7
7664.2 ± 1328.6
2459.8 ± 164.2
491.2 ± 50.3

1002.6 ± 30.7
836.3 ± 123.7
228.0 ± 24.5
150.4 ± 4.2
3800.4 ± 226.1
3542.2 ± 431.8
650.9 ± 88.8
236.8 ± 15.7
4618.6 ± 183.6
2401.4 ± 344.5
553.2 ± 46.8
286.9 ± 11.6
9417.1 ± 862.6
7891.6 ± 984.4
1869.1 ± 197.4
487.5 ± 74.6

749.4 ± 21.4
401.0 ± 40.8
169.0 ± 10.8
144.8 ± 0.3
2301.2 ± 172.6
1256.4 ± 110.8
260.7 ± 10.3
180.8 ± 16.9
1722.5 ± 350.7
1087.8 ± 13.4
342.7 ± 19.3
226.8 ± 21.7
7146.2 ± 419.3
7131.0 ± 552.1
1836.9 ± 236.7
429.2 ± 16.6

Control

127.3

135.4

140.3

143.5

Alexa750-pHLIP-Mutants

Organs
Muscle
Tumor
Liver
Kidney

Time
postinjection
2 hrs
4 hrs
2 hrs
4 hrs
2 hrs
4 hrs
2 hrs
4 hrs

Var3M
n=3

Var7M
n=3

886.2 ± 197.3
774.2 ± 255.2
3444.6 ± 311.3
3355.9 ± 796.2
3954.1 ± 46.2
2313.2 ± 373.7
9114.2 ± 529.2
8615.9 ± 657.4

628.3 ± 24.2
430.1 ± 47.1
2451.8 ± 162.1
1562.9 ± 240.4
1389.4 ± 129.5
902.0 ± 79.4
9691.2 ± 176.0
8275.0 ± 499.0

Control
146.9
144.1
144.2
146.5

Cy5.5-pHLIPs
Organs

Time

WT

Var3

140

Var3-C

Var7

Control

postinjection
2 hrs
4hrs
24hrs
2 hrs
4hrs
24hrs

n=3

n=3

n=3

n=3

634.1 ± 83.7
652.3 ± 88.4
466.5 ± 54.2
2094.8 ± 497.0
2882.6 ± 660.6
2419.5 ± 226.1

918.8 ± 162.6
660.5 ± 36.6
424.2 ± 30.8
3343.2 ± 1526.1
2798.5 ± 395.2
2312.5 ± 556.1

638.0 ± 86.3
467.3 ± 63.0
356.7 ± 16.5
1900.3 ± 293.5
2076.3 ± 531.5
1390.8 ± 141.9

Liver

2 hrs
4hrs
24hrs

4209.2 ± 603.7
3587.1 ± 127.3
2666.9 ± 229.0

8118.0 ± 901.8
5589.0 ± 129.6
1513.1 ± 248.1

Kidney

2 hrs
4hrs
24hrs

2024.9 ± 349.3
1576.9 ± 253.7
947.9 ± 198.0

2641.0 ± 249.2
1998.0 ± 485.3
1135.4 ± 193.9

1035.1 ± 63.4
719.4 ± 113.4
411.3 ± 4.4
3627.7 ± 441.5
3482.0 ± 502.7
2371.9 ± 186.9
7828.1 ±
1161.2
5916.4 ± 843.6
1844.5 ± 437.3
2926.5 ± 223.8
2322.7 ± 335.8
1116.7 ± 28.6

Muscle

Tumor

276.1

316.9

5706.9 ± 719.4
4177.2 ± 278.0
1180.8 ± 197.8

259.5

2729.3 ± 137.4
2416.3 ± 588.9
1335.8 ± 174.5

263.9

IR680-pHLIPs

Organs

Muscle

Tumor

Liver

Kidney

Time
postinjection
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs

WT
n=3

Var3
n=3

Var7
n=3

523.3 ± 32.9
551.6 ± 80.0
353.6 ± 37.5
931.9 ± 18.8
906.3 ± 66.0
426.7 ± 5.5
917.9 ± 144.1
626.3 ± 52.6
305.8 ± 35.3
1053.0 ± 171.0
758.6 ± 137.3
353.6 ± 37.5

619.2 ± 50.7
659.5 ± 56.9
401.9 ± 53.1
1370.8 ± 158.3
1462.7 ± 114.7
645.5 ± 185.8
1119.3 ± 97.7
1020.2 ± 150.4
389.4 ± 53.3
821.8 ± 30.6
830.5 ± 52.5
352.4 ± 89.0

463.5 ± 73.9
401.0 ± 44.6
363.4 ± 23.2
718.9 ± 83.5
597.8 ± 69.8
719.7 ± 34.1
569.2 ± 33.3
427.7 ± 47.2
291.5 ± 33.0
1081.4 ± 76.1
682.6 ± 107.8
311.6 ± 34.1

Control

324.1

333.1

270.3

241.7

IR800-pHLIPs

Organs

Muscle

Tumor

Liver

Kidney

Time
postinjection
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs

WT
n=3

Var3
n=3

Var7
n=3

630.6 ± 53.2
612.6 ± 25.1
255.6 ± 19.7
1684.9 ± 292.6
1996.4 ± 581.3
737.5 ± 241.1
3133.4 ± 179.7
2969.8 ± 512.7
1863.4 ± 201.1
4529.1 ± 547.1
4015.6 ± 861.0
2998.4 ± 314.5

736.4 ± 116.0
747.9 ± 10.5
231.6 ± 21.1
2289.3 ± 146.0
3129.0 ± 176.4
1349.9 ± 267.3
3849.9 ± 164.7
3238.8 ± 127.2
1089.6 ± 165.0
5908.6 ± 128.3
6235.9 ± 470.1
3863.7 ± 478.2

542.9 ± 43.0
359.1 ± 27.7
185.1 ± 14.6
1858.2 ± 271.3
1585.9 ± 165.8
554.9 ± 156.6
2337.0 ± 107.9
1964.7 ± 129.2
972.4 ± 149.9
3885.1 ± 420.8
3238.1 ± 345.6
3696.5 ± 114.7
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Control

127.3

135.4

140.3

143.5

Dy680-pHLIPs

Organs

Muscle

Tumor

Liver

Kidney

Time
postinjection
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs

WT
n=3

Var3
n=3

Var7
n=3

754.9 ± 106.3
694.3 ± 50.6
203.6 ± 4.8
2326.0 ± 183.6
2246.3 ± 627.8
511.7 ± 129.3
1600.0 ± 60.7
1284.6 ± 142.6
331.8 ± 46.2
1886.5 ± 227.5
1728.6 ± 45.4
327.9 ± 29.1

465.4 ± 103.5
533.2 ± 18.3
274.6 ± 15.8
1998.2 ± 394.4
2243.3 ± 103.9
897.0 ± 314.3
1243.7 ± 218.2
984.2 ± 47.5
373.0 ± 49.8
1066.6 ± 119.8
1088.9 ± 73.8
375.4 ± 39.5

345.6 ± 4.7
305.5 ± 16.4
178.9 ± 9.2
1029.3 ± 100.8
847.4 ± 73.5
241.1 ± 7.8
495.5 ± 77.8
431.2 ± 65.6
207.5 ± 20.6
1242.9 ± 119.1
1004.5 ± 250.7
229.8 ± 22.6

Control

172.3

219.0

210.9

160.2

DyP680-pHLIPs

Organs

Muscle

Tumor

Liver

Kidney

Time
postinjection
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs

WT
n=3

Var3
n=3

Var7
n=3

829.6 ± 165.3
735.1 ± 137.6
478.9 ± 24.9
3832.7 ± 769
3679.4 ± 225.9
2716.2 ± 512.0
1968.9 ± 354.6
1726.6 ± 343.2
1290.2 ± 82.3
6047.7 ± 619.5
4757.6 ± 360.8
5010.1 ± 364.3

828.6 ± 389.7
808.5 ± 14.8
406.4 ± 27.0
2883.7 ± 567.7
3104.6 ± 162.4
2239.8 ± 459.6
1614.4 ± 152
1517.9 ± 26.1
650.6 ± 131.0
6584.5 ± 640.1
4896.5 ± 656.5
5269.3 ± 923.6

416.5 ± 22.7
367.0 ± 58.5
291.1 ± 22.2
936.2 ± 132.2
1008.8 ± 166.8
644.9 ± 60.6
488.2 ± 38.9
405.6 ± 71.1
314.1 ± 27.1
5262.3 ± 562.0
5459.7 ± 928.5
4576.4 ± 489.9
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Control

172.3

219.0

210.9

160.2

Table S2. Tumor/muscle, tumor/kidney and tumor/liver ratio values.
Ratios

Time postinjection

WT

Var3

Var7

4.86 ± 0.75
5.29 ± 1.27
9.32 ± 1.45
5.30 ± 0.83
5.23 ± 1.18
2.21 ± 0.52
2.83 ± 0.36
4.09 ± 0.98
9.57 ± 3.14

2.89 ± 0.76
4.62 ± 0.67
4.23 ± 1.00
2.40 ± 0.26
3.36 ± 0.36
1.03 ± 0.38
4.09 ± 0.80
5.60 ± 0.36
3.76 ± 1.02

2.95 ± 0.26
3.61 ± 0.81
3.62 ± 1.66
0.93 ± 0.26
0.85 ± 0.09
0.62 ± 0.16
1.48 ± 0.09
1.61 ± 0.27
2.82 ± 1.04

3.60 ± 0.23
3.09 ± 0.58
2.81 ± 0.63
0.65 ± 0.10
0.45 ± 0.05
0.38 ± 0.14
2.52 ± 0.07
2.51 ± 0.25
2.64 ± 0.70

3.80 ± 0.18
4.33 ± 0.59
2.88 ± 0.30
0.41 ± 0.03
0.45 ± 0.02
0.35 ± 0.04
0.82 ± 0.03
1.48 ± 0.05
1.17 ± 0.04

3.08 ± 0.18
3.14 ± 0.11
1.54 ± 0.03
0.32 ± 0.02
0.18 ± 0.01
0.14 ± 0.01
1.36 ± 0.12
1.15 ± 0.05
0.76 ± 0.04

3.54 ± 0.57
4.23 ± 0.25
5.41 ± 0.53
1.26 ± 0.31
1.42 ± 0.08
2.11 ± 0.47
0.41 ± 0.09

3.02 ± 0.37
4.39 ± 0.32
3.91 ± 0.30
0.70 ± 0.07
0.88 ± 0.15
1.06 ± 0.13
0.34 ± 0.05

Alexa546-pHLIPs
Tumor/Muscle

Tumor/Kidney

Tumor/Liver

2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs

3.62 ± 0.77
4.68 ± 0.57
5.22 ± 1.47
3.13 ± 0.84
5.39 ± 1.70
2.45 ± 0.80
2.31 ± 0.60
2.88 ± 0.62
2.67 ± 1.03
Alexa647-pHLIPs

Tumor/Muscle

Tumor/Kidney

Tumor/Liver

2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs

2.88 ± 0.21
3.25 ± 0.12
2.67 ± 0.44
0.68 ± 0.55
0.75 ± 0.12
0.66 ± 0.04
1.42 ± 0.30
1.34 ± 0.41
1.53 ± 0.28
Alexa750-pHLIPs

Tumor/Muscle

Tumor/Kidney

Tumor/Liver

2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs

3.22 ± 0.18
4.16 ± 0.29
4.06 ± 0.10
0.39 ± 0.03
0.39 ± 0.04
0.46 ± 0.03
0.80 ± 0.05
0.80 ± 0.08
0.82 ± 0.07
Cy5.5-pHLIPs

Tumor/Muscle

Tumor/Kidney
Tumor/Liver

2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs

3.28 ± 0.23
4.50 ± 0.71
5.27 ± 0.63
1.04 ± 0.09
1.83 ± 0.19
2.60 ± 0.20
0.50 ± 0.04
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4 hrs
24 hrs

0.80 ± 0.11
0.91 ± 0.07

0.50 ± 0.03
1.52 ± 0.10

0.49 ± 0.06
1.20 ± 0.14

2.21 ± 0.08
2.22 ± 0.12
1.58 ± 0.28
1.67 ± 0.24
1.76 ± 0.12
1.82 ± 0.23
1.23 ± 0.11
1.45 ± 0.34
1.64 ± 0.32

1.57 ± 0.23
1.50 ± 0.21
1.16 ± 0.13
0.66 ± 0.06
0.89 ± 0.12
1.36 ± 0.25
1.26 ± 0.10
1.40 ± 0.20
1.45 ± 0.12

3.15 ± 0.37
4.18 ± 0.18
5.79 ± 0.67
0.39 ± 0.02
0.50 ± 0.02
0.35 ± 0.05
0.59 ± 0.04
0.97 ± 0.08
1.23 ± 0.12

3.46 ± 0.72
4.45 ± 0.80
2.97 ± 0.61
0.48 ± 0.02
0.49 ± 0.02
0.15 ± 0.04
0.80 ± 0.11
0.80 ± 0.08
0.56 ± 0.07

4.32 ± 0.53
4.21 ± 0.33
3.25 ± 1.02
1.86 ± 0.20
2.06 ± 0.06
2.40 ± 0.90
1.60 ± 0.10
2.29 ± 0.21
2.38 ± 0.64

2.98 ± 0.33
2.77 ± 0.10
1.35 ± 0.03
0.83 ± 0.02
0.87 ± 0.18
1.05 ± 0.07
2.09 ± 0.15
1.99 ± 0.25
1.17 ± 0.08

3.86 ± 1.22
3.84 ± 0.13
5.48 ± 0.84
0.44 ± 0.09
0.64 ± 0.11
0.42 ± 0.03
1.78 ± 0.23
2.05 ± 0.12
3.44 ± 0.02

2.24 ± 0.23
2.78 ± 0.59
2.21 ± 0.04
0.18 ± 0.02
0.19 ± 0.01
0.14 ± 0.02
1.92 ± 0.27
2.49 ± 0.03
2.06 ± 0.19

IR680-pHLIPs
Tumor/Muscle

Tumor/Kidney

Tumor/Liver

2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs

1.79 ± 0.14
1.67 ± 0.26
1.22 ± 0.12
0.90 ± 0.16
1.21 ± 0.17
1.37 ± 0.12
1.03 ± 0.19
1.46 ± 0.18
1.40 ± 0.16
IR800-pHLIPs

Tumor/Muscle

Tumor/Kidney

Tumor/Liver

2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs

2.70 ± 0.66
3.24 ± 0.82
2.88 ± 0.92
0.38 ± 0.09
0.50 ± 0.10
0.24 ± 0.06
0.54 ± 0.07
0.67 ± 0.15
0.39 ± 0.12
Dy680-pHLIPs

Tumor/Muscle

Tumor/Kidney

Tumor/Liver

2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs

3.11 ± 0.29
3.28 ± 1.09
2.51 ± 0.61
1.24 ± 0.29
1.30 ± 0.39
1.58 ± 0.48
1.45 ± 0.09
1.77 ± 0.56
1.53 ± 0.19
DyP680-pHLIPs

Tumor/Muscle

Tumor/Kidney

Tumor/Liver

2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs
2 hrs
4 hrs
24 hrs

4.62 ± 0.19
5.15 ± 1.14
5.65 ± 0.81
0.64 ± 0.15
0.78 ± 0.09
0.55 ± 0.12
1.94 ± 0.14
2.17 ± 0.31
2.11 ± 0.40
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Table S3. Contrast Index (CI) calculated for 2 and 4 hours time points.
Time postinjection

WT

Var3

Var7

Alexa546-pHLIPs
2 hrs
4 hrs

4.06 ± 0.88
5.22 ± 0.61

5.60 ± 0.92
6.01 ± 1.55

3.18 ± 0.90
5.54 ± 0.81

Alexa647-pHLIPs
2 hrs
4 hrs

4.03 ± 0.58
5.12 ± 0.39

3.41 ± 0.35
4.72 ± 1.39

2.61 ± 0.07
7.18 ± 3.70

Alexa750-pHLIPs
2 hrs
4 hrs

3.59 ± 0.40
4.88 ± 0.92

4.19 ± 0.37
4.95 ± 1.28

3.49 ± 0.39
4.13 ± 0.39

Cy5.5-pHLIPs
2 hrs
4 hrs

4.96 ± 0.56
7.16 ± 2.54

4.55 ± 1.19
6.44 ± 0.63

4.58 ± 1.47
9.27 ± 0.37

IR680-pHLIPs
2 hrs
4 hrs

1.79 ± 0.14
1.67 ± 0.26

2.21 ± 0.08
2.22 ± 0.12

1.57 ± 0.23
1.50 ± 0.21

IR800-pHLIPs
2 hrs
4 hrs

3.13 ± 0.87
3.80 ± 0.10

3.61 ± 0.55
4.82 ± 0.21

4.21 ± 1.00
6.37 ± 1.46

Dy680-pHLIPs
2 hrs
4 hrs

3.67 ± 0.48
3.97 ± 1.50

6.27 ± 1.13
5.63 ± 0.56

4.69 ± 0.71
4.72 ± 0.07

DyP680-pHLIPs
2 hrs
4 hrs

5.55 ± 0.40
6.43 ± 1.50

4.99 ± 2.44
4.53 ± 0.15
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2.92 ± 0.36
4.25 ± 1.40

Figure S1. Absorbtion (A) and fluorescence (B) spectra of fluorescent-constructs
measured in PBS.
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